Canopy Growth（CGC）株式概要キャノピー・グロース・コーポレーションは、その子会社とともに、カナダ、ドイツ、米国およびその他の国々において、医療用および成人向けの大麻および大麻関連製品の生産、流通、販売を行っています。 詳細CGC ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より57.1%で取引されている 過去5年間の収益は年間27.8%増加しました。 同業他社や業界と比較して、良好な取引価格 リスク分析過去1年間で株主の希薄化は大幅に進んだ 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るCGC Community Fair Values Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,690 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,690 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.97125.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b547m2016201920222025202620282031Revenue CA$442.0mEarnings CA$64.4mAdvancedSet Fair ValueView all narrativesCanopy Growth Corporation 競合他社Aquestive TherapeuticsSymbol: NasdaqGM:AQSTMarket cap: US$531.9mSNDLSymbol: NasdaqCM:SNDLMarket cap: US$341.0mTilray BrandsSymbol: NasdaqGS:TLRYMarket cap: US$523.7mEvolusSymbol: NasdaqGM:EOLSMarket cap: US$451.1m価格と性能株価の高値、安値、推移の概要Canopy Growth過去の株価現在の株価CA$0.9752週高値CA$2.3852週安値CA$0.84ベータ2.411ヶ月の変化-3.84%3ヶ月変化-7.50%1年変化-14.05%3年間の変化-74.71%5年間の変化-99.50%IPOからの変化-97.06%最新ニュースお知らせ • Jul 08Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026.Reported Earnings • Jun 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: CA$0.88 loss per share (improved from CA$5.62 loss in FY 2025). Revenue: CA$284.6m (up 5.8% from FY 2025). Net loss: CA$262.9m (loss narrowed 56% from FY 2025). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 86%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • May 29Canopy Growth Corporation Relaunches Tweed Brand in Germany with New Mtl Cannabis Strain LineupCanopy Growth Corporation announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp., a wholly-owned subsidiary of the Company. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 2025. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.お知らせ • May 16Canopy Growth Corporation to Report Q4, 2026 Results on Jun 15, 2026Canopy Growth Corporation announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jun 15, 2026お知らせ • May 09Canopy Growth Corporation and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsCanopy Growth Corporation and Spectrum Therapeutics announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. Together, these innovations support improved patient adherence and stronger clinical alignment. Daytime Formulations: Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack. Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack. Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack. Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations: Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack. A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack. Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May.Seeking Alpha • Apr 23Canopy Growth Rallies On Renewed Hope Of Cannabis ReschedulingSummary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha最新情報をもっと見るRecent updatesお知らせ • Jul 08Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026.Reported Earnings • Jun 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: CA$0.88 loss per share (improved from CA$5.62 loss in FY 2025). Revenue: CA$284.6m (up 5.8% from FY 2025). Net loss: CA$262.9m (loss narrowed 56% from FY 2025). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 86%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • May 29Canopy Growth Corporation Relaunches Tweed Brand in Germany with New Mtl Cannabis Strain LineupCanopy Growth Corporation announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp., a wholly-owned subsidiary of the Company. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 2025. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.お知らせ • May 16Canopy Growth Corporation to Report Q4, 2026 Results on Jun 15, 2026Canopy Growth Corporation announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jun 15, 2026お知らせ • May 09Canopy Growth Corporation and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsCanopy Growth Corporation and Spectrum Therapeutics announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. Together, these innovations support improved patient adherence and stronger clinical alignment. Daytime Formulations: Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack. Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack. Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack. Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations: Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack. A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack. Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May.Seeking Alpha • Apr 23Canopy Growth Rallies On Renewed Hope Of Cannabis ReschedulingSummary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking AlphaNew Risk • Apr 04New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$10.0k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$130m net loss in 2 years). Significant insider selling over the past 3 months (US$10.0k sold).お知らせ • Mar 31Canopy Growth Corporation Unveils Deelish Cannabis Brand With High THC At Everyday PriceCanopy Growth Corporation announced Deelish, a new cannabis brand built for the everyday consumer with an everyday price. Deelish is Canopy Growth's newest brand, delivering high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish rotates its genetic lineup regularly, giving consumers access to a curated range of cultivars over time. Deelish launched with four SKUs across formats: Pretty Sweet Sativa 28g Whole Flower | 27-33% THC, Pretty Sweet Sativa 2x1g Pre-roll Joints | 26-32% THC, Pretty Chill Indica 28g Whole Flower | 27-33% THC, Pretty Chill Indica 2x1g Pre-roll Joints | 26-32% THC. Now available at select stores across Ontario and Alberta.お知らせ • Feb 14Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million.Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 18,705,578 Price\Range: $1.03Reported Earnings • Feb 07Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: CA$0.18 loss per share (improved from CA$1.11 loss in 3Q 2025). Revenue: CA$74.5m (flat on 3Q 2025). Net loss: CA$62.6m (loss narrowed 49% from 3Q 2025). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.お知らせ • Jan 23Canopy Growth Corporation to Report Q3, 2026 Results on Feb 06, 2026Canopy Growth Corporation announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026お知らせ • Dec 15Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million.Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million on December 14, 2025. Canopy Growth to acquire all of the issued and outstanding common shares in the capital of MTL on the basis of 0.32 of a common share of Canopy Growth (each whole share, a “Canopy Growth Share”) and CAD 0.144 in cash for each MTL Share, or approximately 38 million Canopy Growth Shares and CAD 17 million in cash in the aggregate. Pursuant to the Arrangement, each MC Shareholder will irrevocably, finally and fully release MTL, Canopy Growth and their respective affiliates from any and all obligations owing to such MC Shareholder pursuant to the Share Exchange Agreement, including for greater certainty, each MC Shareholder’s entitlement to anti-dilution rights pursuant to the Share Exchange Agreement (the “Release”) in exchange for such MC Shareholder’s pro rata entitlement to up to 2,956,391 (subject to reduction in certain circumstances) Canopy Growth Shares to be issued to the MC Shareholders pursuant to the Arrangement. The. Arrangement Agreement provides that a termination fee of CAD 4 million (the “Termination Fee”) will be payable by MTL upon termination of the Arrangement Agreement. Haywood Securities Inc. provided the MTL Cannabis Special Committee with an opinion that, as of December 14, 2025 and based upon and subject to the various assumptions, limitations, qualifications and other matters set forth in such opinion, the consideration to be received by the MTL Shareholders pursuant to the Transaction is fair, from a financial point of view, to MTL Shareholders. The Transaction was unanimously approved by the Board of Directors of Canopy Growth, as well as the Board of Directors of MTL Cannabis (with conflicted directors abstaining), following the unanimous recommendation of a special committee of the MTL Board of Directors (the “MTL Special Committee”). The MTL Special Committee and the Board of Directors unanimously recommended that MTL Shareholders vote in favour of the Transaction after determining the Transaction is fair to the MTL Shareholders and is in the best interests of MTL Cannabis. The Arrangement is subject to the conditions set forth in the Arrangement Agreement, including, among others: (i) approval by the Supreme Court of British Columbia (the “Court”) at a hearing upon the procedural and substantive fairness of the terms and conditions of the Arrangement; (ii) any approvals required under the Competition Act (Canada); and (iii) approval by the shareholders of MTL as required by applicable corporate and securities laws. The shareholders of MTL will be asked to vote on a resolution (the “Arrangement Resolution”) to, among other things, approve the Arrangement at a shareholder meeting to be called for such purpose, certain regulatory approvals, conditional approval of the Toronto Stock Exchange will have been obtained, including in respect of the listing and posting for trading of the Canopy Growth Shares issued as consideration for MTL Shares pursuant to the Arrangement and the MC Shareholder Consideration. Special meeting of MTL shareholders is expected to occur in February 2026, Expected closing by the end of February 2026. Jonathan Sherman of Cassels Brock& Blackwell LLP acted as legal advisor to Canopy Growth Corporation, Daniel Everall?of Farris LLP acted as legal advisor to MTL, Canaccord Genuity Corp. is acting as exclusive financial advisor to Canopy Growth. Paul Hastings LLP are acting as legal counsel to the Company, Haywood Securities Inc. is acting as exclusive financial advisor to the MTL Special Committee and provided a fairness opinion to the MTL Special Committee.New Risk • Dec 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$50m net loss next year).お知らせ • Dec 04Canopy Growth Corporation Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape SegmentCanopy Growth Corporation announced the national launch of Claybourne Gassers, a new lineup of All-in-One (AIO) vapes featuring liquid diamonds. The launch marks Claybourne's entry into Canada's vape category, building on its leadership in high potency infused products. The Claybourne Gassers collection includes three0.95g liquid diamondvapes: Infused Grape Gasolina (Indica): grape, diesel, pungent; Infused Blue Dream (Sativa): berry, blueberry, sweet; Infused Lemon Cherry G (Hybrid): lemon, cherry, sweet. Each vape contains 92-98% THC, a digital display, variable voltage, and anti-burn, anti-clog technology, all housed in a rechargeable USB-C palm-style format engineered for consistency and clean performance. Alongside Gassers, Claybourne Frosted Flyers are also launching in a new variety 8-pack (8x0.35g) featuring top-selling strains Grape Gasolina (Indica), Blue Dream (Sativa), and a mixed Berry Pack (Hybrid) with a combination of both strains. Each variety pack offers 33-36% THC in a convenient 0.35g format delivering Claybourne's signature potency and flavour. Claybourne Gassers and Claybourne Frosted Flyers variety 8-pack infused pre-rolls are now available at licensed retail stores and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.お知らせ • Nov 19Canopy Growth Corporation Expands Spectrum Therapeutics Portfolio in Australia with New SoftgelsCanopy Growth Corporation has expanded its Spectrum Therapeutics portfolio in Australia with the availability of new softgel capsules, further enhancing the Company's medical cannabis offerings in the region. The formats include Spectrum Yellow Cannabis Oil Softgels (CBD 20mg), Spectrum Red Cannabis Oil Softgels (THC 10mg), and Spectrum Blue Cannabis Oil Softgels (Balanced THC 2.5mg: CBD 3.75mg). These softgels complement Spectrum Therapeutics' existing oils and flower, as well as flower products from Tweed, 7ACRES, and TWD already available to Australian patients. As Australia's medical cannabis market continues to mature, expanding Spectrum Therapeutics' portfolio further strengthens Canopy Growth's presence in the region.Reported Earnings • Nov 09Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: CA$0.006 loss per share (improved from CA$1.52 loss in 2Q 2025). Revenue: CA$66.7m (up 5.9% from 2Q 2025). Net loss: CA$1.64m (loss narrowed 99% from 2Q 2025). Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) exceeded analyst estimates by 94%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.お知らせ • Oct 24Canopy Growth Corporation to Report Q2, 2026 Results on Nov 07, 2025Canopy Growth Corporation announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Nov 07, 2025お知らせ • Oct 14Canopy Growth Corporation Announces Executive AppointmentsCanopy Growth Corporation at its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025, approved the election of Shan Atkins to serve as directors of the Company until the Company’s next annual shareholders meeting or until his or her successor is duly elected or appointed.お知らせ • Sep 17Canopy Growth Appoints Tom Stewart as Chief Financial Officer, Effective September 17, 2025Canopy Growth Corporation announced that Tom Stewart has been appointed Chief Financial Officer, effective September 17, 2025. Mr. Stewart’s appointment supports the continued execution of Canopy Growth’s fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progress already underway to strengthen the Company’s balance sheet, Mr. Stewart’s leadership will play a key role in driving further performance in the quarters ahead. Mr. Stewart has served as Canopy Growth’s Interim Chief Financial Officer since July 2025 and has been a member of the Company’s senior finance leadership team since 2019. During this time, he has helped lead critical initiatives to stabilize the Company’s financial position, reduce expenses, and improve the Company’s liquidity position through disciplined debt repayments and capital raised via the Company’s “at-the-market” programs.お知らせ • Aug 30+ 1 more updateCanopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million.Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million. Security Name: Common Stock Security Type: Common Stock Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,006,528 Price\Range: $1.328159 Transaction Features: At the Market OfferingReported Earnings • Aug 10First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: CA$0.22 loss per share (improved from CA$1.63 loss in 1Q 2025). Revenue: CA$72.1m (up 8.9% from 1Q 2025). Net loss: CA$41.5m (loss narrowed 68% from 1Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in the US.お知らせ • Aug 08Canopy Growth Corporation Appoints Margaret Shan Atkins to Its Board of Directors, Effective August 6, 2025Canopy Growth Corporation announced the appointment of Margaret Shan Atkins to its Board of Directors, effective August 6, 2025. Ms. Atkins brings extensive experience in retail strategy and operations, consumer goods, wholesale distribution, cybersecurity oversight, accounting and finance, and private investment in both the U.S. and Canada. Ms. Atkins is a former partner in the consumer and retail practice of international consultancy Bain & Company where she developed and executed strategic plans for major retail organizations. She also served as a C-suite executive at a Fortune 15 public retailer, where she led a multi-billion-dollar business unit. She presently serves on the boards of two U.S. public companies – Darden Restaurants (NYSE: DRI) and SpartanNash, where she chairs the audit committee at both companies and serves on the Governance and Nominating Committee at Darden and the Compensation Committee at SpartanNash. During the past five years, Ms. Atkins also served on the following public company boards of directors: Aurora Cannabis Inc., a Canadian cannabis company, from 2019 to 2023; SunOpta Inc., a North American manufacturer of natural and organic food products, from 2014 to 2019; LSC Communications Inc., a leading provider of long and short-run printing services to the book, catalog and magazine publishing industries, from 2016 to 2021.お知らせ • Aug 05Canopy Growth Corporation Expands Global Medical Portfolio with Launch of 7ACRES in AustraliaCanopy Growth Corporation has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company’s medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES’ top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. The introduction of 7ACRES complements Canopy Growth’s existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth’s focus on building a scalable medical platform across international markets.お知らせ • Jul 31Canopy Growth Corporation Announces Appointment of Miles Worne as Managing Director of European Markets, Effective August 11, 2025Canopy Growth Corporation announced the appointment of Miles Worne as Managing Director of European Markets, effective August 11, 2025. Mr. Worne will be responsible for leading the Company’s commercial operations and go-to-market execution across the region. His appointment reflects a strategic investment in Europe, where Canopy Growth aims to deepen its presence in established medical markets and build the capabilities needed to support long-term expansion as new opportunities emerge. Mr. Worne is an experienced commercial leader with over 20 years of global experience across the cannabis, healthcare, and consumer sectors. Most recently, he served as President of Curaleaf International, where he led the expansion of the company’s European medical cannabis operations. His background includes senior leadership roles in Europe, North America, and Asia at Glanbia Performance Nutrition and SlimFast International. Mr. Worne brings a strong track record of driving growth, building teams, and scaling businesses in regulated markets.お知らせ • Jul 25Canopy Growth Corporation to Report Q1, 2026 Results on Aug 08, 2025Canopy Growth Corporation announced that they will report Q1, 2026 results Pre-Market on Aug 08, 2025お知らせ • Jul 10Canopy Growth Corporation Launches Deep Space Infused Pre-RollsCanopy Growth Corporation has launched Deep Space Infused pre-rolls, a high-potency pre-roll joint innovation that brings the brand's signature boldness into one of the fastest-growing categories in cannabis. Deep Space Infused pre- rolls combine high-quality flower with liquid diamonds and THCA diamonds to deliver THC levels above 60%. Offered in a 3x0.5g format, the initial lineup includes two terpene-rich flavours: Milky Way Melon Infused and Big Bang Berry Infused. As Canopy's brand focused on bold formats and high-potency experiences, Deep Space pre-rolls are uniquely positioned to meet the needs of consumers seeking stronger, more flavour-forward products. This launch follows recent Deep Spacebeverage and gummy innovations introduced earlier this year, and builds on the momentum of Claybourne's Frosted Flyers, which have continued to gain traction since launching in November 2024. Together, these offerings strengthen Canopy's position in infused formats and reflect the Company's commitment to targeted innovation in high-growth segments. Deep Space Infused pre -rolls are now available at licensed in-store and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.お知らせ • Jul 09+ 1 more updateCanopy Growth Corporation Appoints CFO ChangesCanopy Growth Corporation announced the appointment of Tom Stewart as Interim Chief Financial Officer, effective immediately. Mr. Stewart succeeds Judy Hong, who served as Canopy Growth’s Chief Financial Officer since April 2022. During her tenure, Ms. Hong played a key role in improving the Company’s capital structure and significantly strengthening its financial position. Canopy Growth thanks Ms. Hong for her leadership and support of its strategic vision. Mr. Stewart is an accomplished finance executive with over 20 years of experience with public companies, including accounting, reporting, FP&A, and operational finance. He joined Canopy Growth in 2019 as Chief Accounting Officer, following 10 years in increasingly senior finance roles at Constellation Brands Inc. Mr. Stewart began his career at PricewaterhouseCoopers and is a Certified Public Accountant in the state of New York. Mr. Stewart’s appointment is part of the Company’s continued execution of its Fiscal 2026 strategy, which includes a sharpened focus on operational efficiency, disciplined capital management, and building a sustainable, performance-led business. His background in performance-driven consumer packaged goods finance and accounting makes him well-suited to support Canopy Growth’s financial and operational priorities in this next phase.New Risk • Jul 01New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$71k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (146% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$177m). Currently unprofitable and not forecast to become profitable over next 2 years (CA$93m net loss in 2 years). Significant insider selling over the past 3 months (US$71k sold).Recent Insider Transactions • Jun 20CFO & Principal Accounting Officer recently sold US$57k worth of stockOn the 16th of June, Judy Hong sold around 39k shares on-market at roughly US$1.47 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Judy has been a net seller over the last 12 months, reducing personal holdings by US$365k.Reported Earnings • May 30Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: CA$5.62 loss per share. Revenue: CA$269.0m (down 9.5% from FY 2024). Net loss: CA$604.1m (loss widened 25% from FY 2024). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 27%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$177m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$177m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$106m net loss in 2 years).お知らせ • May 06Canopy Growth Corporation Drives Innovation in High-Demand Segments with Latest Product LaunchesCanopy Growth Corporation has launched a series of product innovations targeting Canada's fastest-growing adult-use categories. The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This fresh lineup strengthens Canopy's presence in core formats and is backed by its brands. Tweed and 7ACRES anchor the portfolio with consistent, high-quality offerings, Claybourne builds on strong momentum in key markets, and Deep Space returns to the edibles category. Canopy Growth's latest introductions include: Advanced All-in-One Vapes with CCELL Technology: Canopy Growth is introducing CCELL's newest all-in-one ("AIO") vape technology to the Canada adult-use market through Tweed and 7ACRES. The advanced hardware includes a built-in display screen for variable voltage and battery life, offering a more functional and enhanced experience. This launch supports Canopy's strategy to deepen its presence in high demand vape formats. Tweed is launching three new 0.95g liquid diamond AIO vapes: Gorilla Berry Grape, Blood Orange Kush, and Kush Mints. 7ACRES is introducing 0.95g AIO vapes in Blue Dream and Jack Haze with a curated blend of live resin and liquid diamonds. New Flower Genetics from Tweed Tweed is releasing two new high-THC cultivars - Sour Sucker Mints and Blood Orange Kush, both testing above 28% THC. Sour Sucker Mints crosses Ultra Sour and Kush Mints offering a sharp citrus bite, balanced by sweet mint and gassy undertones. Recent harvests are testing between 3.25-4% total terpenes. Expanded Offerings in Pre-rolls and Infused PRJs: Pre-rolls remain one of the most in-demand formats in Canada's adult-use market, and Canopy Growth is expanding its offerings to meet evolving consumer preferences. Claybourne Frosted Flyers, Canada's fastest growing pre-roll brand,3 is adding two new flavours: Watermelon Z and Infused Super Sour Apple -and a new 5x0.5g format alongside the original 3x0.5g offering. Tweed expands its Quickies line with Sour Sucker Mints and blood Orange Kush in a 10x0.35g format. 7ACRES is introducing 3x0.5g infused Live ResinBlue Dream and Jack Haze pre-rolls. In addition, 7ACRES is launching live resin-infused hash in Blue Dream and Jack Hazing - offering another format option for high-THC consumers. Deep Space Expands into Gummies: Deep Space, known for its strong following in cannabis beverages, is re-entering the edibles category with ario of gummies - building on the brand's high-potency positioning. Sour Pulsar Peach, Sour Strawberry void, and Blue Sourberry. Each pack contains one10mg THC gummy and naturally occurring caffeine, offering a flavour-forward functional experience. These new products from Canopy Growth are now available at licensed in-store and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$107m net loss in 2 years).Seeking Alpha • Apr 22Canopy Growth: Zombie Financials As Delisting Threat LoomsSummary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alphaお知らせ • Apr 05Robbins LLP Informs Stockholders of the Canopy Growth Corporation Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Canopy Growth Corporation securities between May 30, 2024 and February 6, 2025. Canopy, together with its subsidiaries, produces, distributes, and sells cannabis and hemp-based products for recreational and medical purposes. The Allegations: Robbins LLP is Investigating Allegations that Canopy Growth Corporation (CGC) Misled Investors Regarding its Cost Reduction Measures According to the complaint, during the class period, defendants failed to disclose that: (i) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (ii) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company's gross margins and overall financial results; and (iii) accordingly, defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same. On February 7, 2025, Canopy announced disappointing financial results "primarily due to the incremental costs related to the Claybourne infused pre-roll launch in Canada, and an increase in indirect costs of Storz & Bickel vaporizer devices.お知らせ • Apr 02Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis BrandCanopy Growth Corporation has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation - featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a regular basis based on patient needs, preferences, and feedback. The strains which generate the most positive and consistent customer feedback will remain in market, while others will be phased out to make way for new genetics through a process of constant enhancement. This approach will help Spectrum Therapeutics consistently deliver new, premium quality strains to the medical cannabis market in Canada. The first release under the Spectrum Reserve brand features four flower strains, each selected for the combination of their potency and terpene profile: Power Plant x Super Silver Haze (Indica, 22-25% THC): A rich, woody and earthy aroma, with a sharp, peppery taste and 2.21% total terpenes. Grape Star x Golden Lemons (Sativa, 22-25% THC: With a dank white grape aroma, this strain features 1.77% total terpenes, offering a smooth, uplifting experience. Malawi x Kosher Tangie (Hybrid, 27-30% THC): A complex citrus and chocolate flavour profile, complemented by a pungent, earthy aroma, with 2.59% total terpenes. Raspberry Parfait (Sativa-Dominant Hybrid, 22-27% THC): With 2.59% total ter Penes, this strain features aum, berry, and violet aroma for a rich and flavorful experience.Seeking Alpha • Mar 30Cannabis Investors Should Sell Canopy GrowthSummary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alphaお知らせ • Mar 19Canopy Growth Corporation to Report Q4, 2025 Results on May 30, 2025Canopy Growth Corporation announced that they will report Q4, 2025 results on May 30, 2025お知らせ • Mar 01+ 1 more updateCanopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million.Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,747,064 Price\Range: $7.116078 Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,058,788 Price\Range: $5.653206 Security Name: Common Stock Security Type: Common Stock Securities Offered: 22,713,177 Price\Range: $3.594743 Transaction Features: At the Market OfferingSeeking Alpha • Feb 17Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains WeakSummary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking AlphaReported Earnings • Feb 07Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: CA$1.11 loss per share (improved from CA$2.78 loss in 3Q 2024). Revenue: CA$74.8m (down 4.8% from 3Q 2024). Net loss: CA$121.9m (loss narrowed 47% from 3Q 2024). Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 95%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.Seeking Alpha • Feb 06Canopy Growth: Still A Disaster Heading Into Fiscal Q3 ResultsSummary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alphaお知らせ • Jan 24Canopy Growth Corporation to Report Q3, 2025 Results on Feb 07, 2025Canopy Growth Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 07, 2025Seeking Alpha • Jan 22Crashing Canopy Growth Is Still Not A BuySummary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking AlphaNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$124m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change).Seeking Alpha • Jan 11Canopy Growth Remains Undervalued Amidst Cannabis Sector UncertaintySummary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alphaお知らせ • Dec 05Canopy Growth Corporation Launches Two Holiday-Inspired Cannabis Products from Tweed, Including A Sugar-Free Cranberry Ginger Ale and Tweed Snowtorious 91K FlowerCanopy Growth Corporation announced the launch of two holiday-inspired cannabis products from Tweed, including a sugar-free Cranberry Ginger Ale and Tweed Snowtorious 91K flower, to bring a little extra cheer to the season's festivities. Tweed Cranberry Ginger Ale pays homage to a classic Canadian favourite, reimagined for the holidays. Enjoy this sugar-free cannabis beverage with 10mg of THC. Tweed Snowtorious 91 K. This holiday-inspired flower is a true seasonal delight. Tweed Snowtorious91K is a bold and frosty indica with minty and diesel aromas. It's a cross between popular cultivars Kush Mints (Animal Mints x Bubba Kush) and 91K (Chemdawg 91 x OG Captain Krypt), set to bring some holiday magic to any winter scene. If you're looking for a stocking stuffer or want something personal to celebrate the end of a long year, 7ACRES Ultra Jack flower and Claybourne Frosted Flyers Infused Pre-Rolls offer a high quality and premium experience for any enthusiast. 7ACRES Ultra Jack. With aromas that evoke the holidays, 7ACRES Ultra Jack is a terpene rich sativa-dominant hybrid created by crossing cultivars Ultra Sour with renowned 7ACRES Jack Haze. Experience a citrus kick with undertones of earthy spice. Claybourne Froster Flyers. Experience some California love this holiday season with Claybourne's Frosted Flyers infused pre-rolls. New in Canada, Claybourne Frosted Flyers offer high potency and nonstop flavour from start to finish and are available in Blue Dream, Strawberry Cough, Pineapple Express, Grape Gasolina, and Banana OG as part of a 1.5g 3-pack or a 5 x 0.5g (2.5g total) Variety Pack. These offerings from Canopy Growth will be available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions in addition to the Spectrum Therapeutics online store for authorized medical cannabis consumers.お知らせ • Nov 26+ 1 more updateCanopy Growth Corporation Appoints Luc Mongeau as Chief Executive Officer, Effective January 6, 2025Canopy Growth Corporation announced that the company's board of directors has named current Board member and CPG-veteran, Mr. Luc Mongeau, as the next Chief Executive Officer (CEO) of the company effective January 6, 2025. A seasoned executive with broad CPG experience, Mr. Mongeau has most recently served as the CEO of North America's leading e-commerce provider for residential and commercial furniture. He has previously held the role of President for Weston Foods as well as President of Mars Petcare North America. Since joining the Board as an observer in early 2023 and as a Board member in February 2024, Mr. Mongeau has played a key role in shaping the company's strategy. This has included a focus on driving asset-light expansion across canopy Growth's core markets, as well as actions to achieve near term profitability as the company meets the vast opportunities presented by the global cannabis market. Mr. Mongeau will remain a member of the Board in his new role as CEO, and to support an efficient transition, Mr. Klein will continue in his role as CEO and a director on the Board until the effective date of Mr. Mongeau's appointment as CEO on January 6, 2025. With a proven track record of leading and elevating organizations, Mr. Mongeau joins Canopy Growth with over 25 years' experience as a senior executive. He has demonstrated expertise in marketing, sales, supply chain operations, and M&A. Most recently as the CEO of ESolutions Furniture, formerly Bestar-Bush, Mr. Mongeau led the transformation of the business to deepen its share of the highly competitive digital commerce furniture industry. This included implementing a new approach to design and sourcing, reconfiguring the North American manufacturing network, and enhancing the company's global supply chain. Prior to this, during Mr. Mongeau's five-year tenure as President of Weston Foods, he spearheaded the strategic realignment and end-to-end operational leadership of the $2 billion North American bakery, overseeing a team of over 6,000 employees across 40 facilities. He directed the development of commercial strategies across branded and private label categories for major North American retailers and managed the sale of Weston Foods. Additionally, in his role as President of Mars Petcare North America, Mr. Mongeau provided strategic and operational leadership to a $3 billion North American organization with more than 3,000 employees, 27 manufacturing sites, and three distinct operating units within both branded and private label categories. Mr. Mongeau holds a Bachelor of Science from the Université de Sherbrooke and an MBA from the Ivey School of Business at Western University. He has also completed executive education at Harvard Business School.お知らせ • Nov 21Canopy Growth Launches Claybourne Infused Pre-Rolls in CanadaCanopy Growth Corporation announced through an exclusive licensing agreement the launch of California grown Claybourne brand in Canada. This initial launch brings Claybourne's Frosted Flyers Infused Pre-Rolls to Canadian medical and adult-use consumers in five distinct offerings, Blue Dream, Strawberry Cough, Pineapple Express, Grape Gasolina and Banana OG. Each Frosted Flyer is high potency and packed with nonstop flavor from start to finish. Claybourne Frosted Flyers Infused Pre-Rolls offer higher potency, unrivaled smokability and consistent flavour. This is achieved through a multi-step innovative, artisanal and hand-made approach to crafting the final product through: Diamond Frosting: a unique, flavourless THCa coating on the outside of the joint provides added potency and contributes to a consistent, full flower flavour experience from beginning to end. Liquid Diamond Infusion: added concentrated THC in the form of diamonds. Terpene Enhanced: an additional infusion of natural terpenes to help accent the bold flavours of your favourite flower. Premium Indoor Full Nug Flower: made with 100% indoor cultivated flower. Claybourne Frosted Flyers Infused Pre-Rolls will be available in five offerings – each as part of a 1.5G 3-pack, as well as a 5 x 0.5G (2.5G total) Variety Pack. Blue Dream 3x0.5g pack (sativa): 42-48% THC (myrcene, pinene and caryophyllene), Strawberry Cough 3x0.5g pack (sativa): 42-48% THC (myrcene, pinene and caryophyllene), Pineapple Express 3x0.5g pack (hybrid): 42-48% THC (myrcene, pinene and caryophyllene), Grape Gasolina 3x0.5g pack (indica): 42-48% THC (myrcene, linalool and caryophyllene), Banana OG 3x0.5g pack (indica): 42-48% THC (limonene, myrcene and caryophyllene), Variety Pack 5x0.5g pack (Sa-Hybri-Ca): 36-40% THC. Through a combination of homegrown innovation and collaborations with the biggest brands in cannabis, like Claybourne, Canopy Growth is strategically positioned to further advance its leadership in this category. New Claybourne pre-roll offerings will be available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions in addition to the Spectrum Therapeutics online store for authorized medical cannabis consumers.Seeking Alpha • Nov 10Avoid Canopy GrowthSummary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking AlphaReported Earnings • Nov 10Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: CA$1.52 loss per share (improved from CA$1.86 loss in 2Q 2024). Revenue: CA$63.0m (down 9.5% from 2Q 2024). Net loss: CA$131.6m (loss narrowed 1.4% from 2Q 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 192%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.Seeking Alpha • Oct 05Canopy Growth: Weak Fundamentals And Growth Acceleration ChallengesSummary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking AlphaRecent Insider Transactions • Aug 27Insider recently sold US$103k worth of stockOn the 22nd of August, Christelle Gedeon sold around 17k shares on-market at roughly US$6.14 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$388k more than they bought in the last 12 months.Seeking Alpha • Aug 27Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End HighSummary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alphaお知らせ • Aug 16David Klein Announces to Retire as CEO of Canopy Growth CorporationCanopy Growth Corporation announced that Mr. David Klein, CEO of the company, will be retiring at the conclusion of the Company's current fiscal year ending March 31, 2025. Until this date or such time that a successor is named, Mr. Klein will continue in his role as CEO and as a member of the Company's Board of Directors to advance Canopy Growth's strategic objectives including profitability and ensure an effective transition. The Board is in the process of securing a globally recognized search firm to initiate a comprehensive CEO selection process focused on identifying a candidate with the right mix of skills, experience, and expertise to lead the Company in its next chapter of growth. Since joining Canopy Growth as CEO in January of 2020, Mr. Klein successfully led the transformation and development of Canopy Growth to meet the vast opportunities presented by the global cannabis market. Under his leadership, the Company established a foundation for multi-market cannabis leadership through its transformation to an asset light model in Canada and across a range of international markets, including Germany. In addition, Mr. Klein oversaw the launch and advancement of Canopy USA as a first of its kind structure to offer the Company's shareholders unique exposure to the rapid growth and opportunity presented by the U.S. cannabis market ahead of federal permissibility.Reported Earnings • Aug 11First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: CA$1.63 loss per share (further deteriorated from CA$0.12 loss in 1Q 2024). Revenue: CA$66.2m (down 13% from 1Q 2024). Net loss: CA$129.2m (loss widened CA$122.4m from 1Q 2024). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in the US.お知らせ • Aug 06Canopy Growth Corporation to Report Q2, 2025 Results on Nov 12, 2024Canopy Growth Corporation announced that they will report Q2, 2025 results on Nov 12, 2024お知らせ • Jul 26Canopy Growth Corporation to Report Q1, 2025 Results on Aug 09, 2024Canopy Growth Corporation announced that they will report Q1, 2025 results Pre-Market on Aug 09, 2024お知らせ • Jul 09Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024.Buy Or Sell Opportunity • Jul 01Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$6.39. The fair value is estimated to be US$8.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has grown by 12%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 44% per annum over the same time period.Buy Or Sell Opportunity • Jun 27Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to US$6.63. The fair value is estimated to be US$5.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has grown by 12%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 69% per annum over the same time period.Seeking Alpha • Jun 17Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alphaお知らせ • Jun 08Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million.Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Jun 04Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: CA$6.22 loss per share (improved from CA$70.69 loss in FY 2023). Revenue: CA$297.1m (down 26% from FY 2023). Net loss: CA$465.2m (loss narrowed 86% from FY 2023). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in the US.Seeking Alpha • Jun 03Canopy Growth: Another Ugly Cannabis ReportSummary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alphaお知らせ • May 18Canopy Growth Corporation to Report Q4, 2024 Results on May 30, 2024Canopy Growth Corporation announced that they will report Q4, 2024 results Pre-Market on May 30, 2024New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).Seeking Alpha • Apr 26Canopy Growth Set For U.S. Cannabis MarketsSummary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking AlphaBoard Change • Apr 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chair of the Board Dave Lazzarato was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 20Canopy Growth Corporation Announces Board and Committee ChangesCanopy Growth Corporation announced in connection with the termination of the Investor Rights Agreement and subsequent to the Note Exchange, on April 18, 2024, Garth Hankinson, Judy Schmeling and James Sabia (collectively, the CBG Nominees) each provided notice to the Company of his or her decision to resign from the Board effective immediately (the CBI Resignations). Each of the CBG Nominees had been a nominee of the CBG Group under the Investor Rights Agreement. Ms. Schmeling had served as Chair of the Board and as a member of the Audit Committee of the Board, and Mr. Sabia had served as a member of the Corporate Governance, Compensation and Nominating Committee of the Board (the CGCN Committee). None of the CBI Resignations were the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Following the CBI Resignations, the Board is now comprised of: David Lazzarato (Chair of the Board, Member of the Audit Committee and Member of the CGCN Committee); Willy Kruh (Director and Chair of the Audit Committee); Theresa Yanofsky (Director, Chair of the CGCN Committee and Member of the Audit Committee); Luc Mongeau (Director and Member of the CGCN Committee); and David Klein (Chief Executive Officer and Director).New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).Seeking Alpha • Mar 22Canopy Growth Is Climbing, But It Won't LastSummary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alphaお知らせ • Feb 22Canopy Growth Launches New Pre-Rolls from 7Acres and HiwayCanopy Growth Corporation announced the introduction of five new pre-roll products across the Company's adult-use cannabis portfolio from brands 7ACRES and Hiway. 7ACRES Smooth Burners 2x0.7g cannabis pre-rolls feature a hybrid designed to deliver the smoothest and slowest burn. Smooth Burners derive from GMO Zkittlez x Funky Zktlz lineage and feature 22-28% THC. 7ACRES Smooth Burners 0.7g are built for a slow burning and smooth smoking experience a unique filter design to optimize airflow and ensure a smooth smoke, 7ACRES Smooth Burners are also relightable and crafted for those on the go who may want to reenjoy later. For those looking for high-quality in a value package, Hiway Water Hash Infused pre-rolls 3x0.5g deliver the goods. Developed for high THC, with a flavourful selection of blended indica or sativa cultivars. With nothing additional added, Hiway Water Hash Infused pre-rolls offer pure dried cannabis and bubble hash evenly rolled for a smooth burn. For those looking for variety, convenience, and a large pack size, Hiway Roadies 20x0.35g are offered in sativa and indica with both options coming in with 18-24% THC. Strains may change from lot to lot allowing consumers to try a variety of batches offering an original, new, and pre-roll experience. With high THC and minimal CBD, Hiway Roadies 20x0.35g are the ultimate in high value.Reported Earnings • Feb 11Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: CA$2.78 loss per share. Revenue: CA$78.5m (down 7.5% from 3Q 2023). Net loss: CA$230.3m (loss widened 3.8% from 3Q 2023). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.お知らせ • Feb 10Canopy Growth Corporation Announces Board ChangesCanopy Growth Corporation announced that Robert L. Hanson has resigned from it's Board of Directors, effective as of February 6, 2024. As part of the advancement of Canopy USA, and the expected departure of CBI appointed Board members following the creation of the Exchangeable Shares, Canopy Growth announced the appointment of two new Board members, Willy Kruh and Luc Mongeau, to the Company's Board, effective as of February 7, 2024. Willy Kruh – Director, Member of the Audit Committee: Willy J. Kruh CPA, CA, MBA, is a retired Partner and Global (and Canadian) Chairman of Consumer and Retail at KPMG LLP, with over 35 years of experience. As a recognized and trusted, advisor, consultant, and auditor, Willy has been instrumental in shaping the financial landscape of leading consumer packaged goods ("CPG"), retail, food, and beverage, multinational corporations, offering strategic guidance and invaluable insights to industry leaders in North America and globally. Willy brings wide ranging financial as well as consumer and retail industry experience to the Board.Luc Mongeau – Director, Member of the Corporate Governance, Compensation & Nominating Committee: Luc Mongeau is a seasoned executive with over 25 years of experience spearheading multi-billion-dollar CPG companies throughout North America, including Weston Foods, Mars and Mars Petcare. An established leader with a demonstrated track record of marketing and sales agility, Luc has consistently delivered transformative growth and operational excellence in brand led businesses. Luc brings his extensive experience in business transformation and strategic leadership to the Board.New Risk • Feb 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$51m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Significant insider selling over the past 3 months (US$94k sold).お知らせ • Feb 08Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED) on February 7, 2024. KeyLeaf is now POS Biosciences Corp., a wholly owned subsidiary of Bioriginal Food & Science Corp. KeyLeaf Life Sciences will operate independently, guided by Jim Shields, the new Managing Director. Bioriginal Food & Science Corporation completed the acquisition of KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED) on February 7, 2024.Seeking Alpha • Feb 06Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To ComeSummary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking AlphaSeeking Alpha • Jan 29Canopy Growth: Further Implosion Is Now A Matter Of When Not IfSummary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alphaお知らせ • Jan 24Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis PortfolioCanopy Growth Corporation announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. Tweed Lemon Meringue Pie flower: For consumers not wanting to compromise quality for quantity, Tweed Lemon Meringue Pie is being served up fresh in a large format 28g package. Packed with sativa whole cannabis flower which has been derived from the Lemon Skunk and Cookies `n' Cream lineage, it features terpenes a-Pinene, Myrcene and Limonene. Tweed's Lemon Meringue Pie boasts lemon, citrus and nutty vanilla aromas, is hang- dried, and comes in with a 23-29% THC range. Grown in Kincardine, Ontario facility and packaged with a Boveda humidity control pack to ensure freshness, this new flower offering is full of flavour just like lemon meringue should be. 7ACRES Jack Haze pre-rolls: 7ACRES Jack Haze pre-rolled joints are arriving in a 0.5gx14 large pack and feature the famous sativa- dominant cultivar with a unique combination of sweet citrus, crisp pine, and warm spice notes. With a range of 17-23% THC and a max CBD potency of 25%, 7ACRES Jack Haze was the result of a large- scale genetic selection program with the goal of finding this novel sativa expression. This phenotype stood out among the rest as it possessed both the sweet haze notes characteristic of a haze cultivar, along with a distinct spice aroma. Spectrum Reserve pre-rolls: Exclusive for medical cannabis customers, Spectrum Therapeutics is extending its Spectrum Reserve collection with Alien Breath and (GG#4 x Mendo Breath) pre-roll joints. Coming in a 0.5gx10 large pack of pre-rolls, this hybrid strain delivers a high 22-28% THC range. The flower's berry, fruity, nutty, sour, and chemical notes derive from its Alien Breath and (GG#4 x Mendo Breath) lineage and its terpenes include 3.5% -Caryophyllene, 6% D-Limonene, 6.5% Beta Myrcene, and 10% Pinene (Alpha & Beta). With consumer needs top of mind, Tweed has also introduced four new products featuring CBD and minor cannabinoids in both oil and softgel formats. Tweed CBD:CBG 4:1 Oil: A newly formulated cannabis oil arriving in a 30mL bottle, Tweed CBD:CBG 4:1 is designed to pair with well-being focused daily routines and provides 100 mg/g CBD and 25 mg/g CBG. Tweed CBD:CBG 6:1 Softgels: For those who prefer the convenience and portability of the softgel format, Tweed CBD:CBG 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBG. Tweed CBD:CBN 4:1 Oil: Coming in a 30mL oil format, the Tweed CBD:CBN 4:1 oil offering is designed to become part of a nightly routine and delivers 100 mg/g CBD and 25 mg/g CBN. Tweed CBD:CBN 6:1 Softgels: Another win for those who prefer the convenience of softgels, Tweed CBD:CBN 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBN.お知らせ • Jan 18Canopy Growth Corporation announced that it expects to receive $35.000008 million in fundingCanopy Growth Corporation announced it has entered into subscription agreements of 8,158,510 units at issue price $4.29 per unit for gross proceeds of $35,000,007.9 on January 18, 2024. Each Unit will be comprised of one common share of the Company and one Series A Common Share purchase warrant or one Series B Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share from the Company at a price equal to $4.83. The Series A Warrants will be exercisable immediately following the closing of the Offering for a period of five years from such date and the Series B Warrants will be exercisable for a period commencing on the date that is six-months following the closing of the Offering and ending on the date that is five years following such date. The Company has also agreed to provide the Investors with customary registration rights. The closing of the private placement pursuant to the Subscription Agreements is expected to occur on or about January 19, 2024, subject to Toronto Stock Exchange approval and customary closing conditionsSeeking Alpha • Jan 14Avoid Canopy Growth After Failed Equity SaleSummary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alphaお知らせ • Jan 13Canopy Growth Corporation to Report Q3, 2024 Results on Feb 09, 2024Canopy Growth Corporation announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Jan 09Canopy Growth Corporation announced that it expects to receive $30 million in fundingCanopy Growth Corporation announced a private placement of 6,993,007 units at a price of $4.29 per share for the gross proceeds of $30,000,000 on January 9, 2024. Each unit will be comprised of (a) one common share of the company and one series A Common Share purchase warrant or one Series B Common Share purchase warrant. Each warrant will entitle the holder to acquire one common share from the company at a price equal to $4.83. The transaction is expected to occur on or about January 10, 2024, subject to customary closing conditions.お知らせ • Dec 19Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million on December 18, 2023.Inspirit Management Ltd completed the acquisition of This Works Products Limited from Canopy Growth Corporation (TSX:WEED) on December 18, 2023.お知らせ • Nov 30Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD GummiesCanopy Growth Corporation Partnered with Marquee Brands Partners and Martha Stewart CBD unveiled a new line of need-based CBD gummies, broadening the brand's evolving wellness assortment. Martha Stewart CBD products provide consumers with convenient, plant-based solutions to help people feel their best all day, every day. The new line was developed in response to consumer demand for targeted solutions that address their most common needs: sleep, stress, and the discomfort of aches and soreness. Each product is formulated with higher levels of CBD and powerful co-active ingredients selected for their known efficacy. In partnership with Marquee Brands and Canopy Growth Corporation, a diversified cannabis and cannabinoid-based consumer product company, Martha's new solution-oriented formulations combine her signature elevated flavor profiles with Canopy Growth's unique consumer insights and continuous industry innovation. The result is three delicious, effective, and tailored new offerings: Sleep CBD Gummies: A berry medley with notes of Montmorency cherry, elderberry, and boysenberry. 25 mg CBD: 3 mg Melatonin. 60 ct - $59.99 MSRP. Chill CBD Gummies: A citrus-forward concoction of tangerine, yuzu, and pomelo 25 mg CBD: 50 mg L-Theanine. 60 ct- $59.99 MSRP; Extra Strength CBD Gummies: An orchard-inspired blend of pluot, apricot, and California red peaches; 30 mg CBD. 60 ct - $59.99 MSRP.New Risk • Nov 24New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$107k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$520m). Currently unprofitable and not forecast to become profitable over next 3 years (CA$63m net loss in 3 years). Significant insider selling over the past 3 months (US$107k sold).お知らせ • Nov 17Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and TweedCanopy Growth Corporation announced the addition of four new flower product offerings from iconic brands 7ACRES and Tweed just in time for the holiday season. New products rolling out under Canopy Growth's flower portfolio include: 7ACRES Holiday Taster Pack - The holidays are arriving early this year with the launch of two flavourful holiday-inspired flower harvests. 7ACRES Holiday Taster Pack (2x7g) 14g featuring strains Ultra Jolly Jack and Peppermint Krypt is now available for purchase. Ultra Jolly Jack is a Sativa-dominant cross of Jack Haze and Ultra Sour strain lineage, creating afestive aroma that features holiday spices alongside earthy and lemon undertones. Complementing Ultra Jolly Jack is the Indica-dominant hybrid Peppermint Krypt, with its sweet and spicy holiday aromas as well as creamy undertones thanks to the cross between frosty Kush Mints and 91K.Both strains feature a 24-30% THC range, are hang dried, and packaged with a Boveda pack to ensure freshness, making the 7ACRES Holiday Taster Pack a thoughtful gift for consumers looking for convenience, variety, and a high-quality experience. Tweed Gorilla Berry and Chemsicle: Given the pressures of the holiday season, Tweed is making it easy to unwind with two new whole flower offerings, Tweed Gorilla Berry and Tweed Chemsicle. Tweed Gorilla Berry is an Indica whole cannabis flower born from the Frosted Kush x Gorilla and Triangle Kush x Blueberry lineage, and features terpenes Terpinolene, ß-Caryophyllene, and ß- Pinene. Bringing forth the sweetness of the holidays, Tweed Gorilla Berry boasts berry and citrus flavours, a gassy aroma, and a 28-34% THC range, making it a perfect stocking (or pipe) stuffer for those looking for full flavour and superior quality. If you're seeking more spice in the seasonal celebrations, Tweed's Chemiscle is a great choice as the Sativa whole flower offers a creamy, spicy, and earthy flavor and aroma. Derived from 91K and Chemdawg lineage, Chemiscle has a 24-30% THC range with terpenes including ß-Myrcene, ß- Pinene, -Pinene. Both strains are packaged with Boveda 2-way humidity control packs and come in 14g whole flower formats. 7ACRES and Tweed's new flower offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions.New Risk • Nov 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$520m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$520m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).Reported Earnings • Nov 10Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.19 loss per share (improved from CA$0.47 loss in 2Q 2023). Revenue: CA$69.6m (down 41% from 2Q 2023). Net loss: CA$133.4m (loss narrowed 40% from 2Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 163%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Garth Hankinson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 20Canopy Growth Corporation announced that it expects to receive $24.99312 million in fundingCanopy Growth Corporation announced a private placement and entered into into subscription agreements with certain institutional investors to issue 22,929,468 units at a price per Unit of $1.09 for the gross proceeds of $24,993,120.12 on September 18, 2023. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share from the Company at a price equal to $1.35 for a period of five years from the date of issuance. The closing of the private placement pursuant to the Subscription Agreements is expected to occur on or about September 19, 2023, subject to customary closing conditions. The Investors also hold an over-allotment option to acquire up to an additional 22,929,468 Units at a price per Unit of $1.09 for aggregate gross proceeds of $24,993,120.12 at the discretion of the Investors at any time on or before November 2, 2023 (the “Over-Allotment Option”).お知らせ • Aug 23Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum TherapeuticsCanopy Growth Corporation announced the addition of five new pre-roll flower product offerings from iconic brands Tweed, 7ACRES, and for the first time, from Canopy Growth's medical cannabis company, Spectrum Therapeutics. New products rolling out under Canopy Growth's flower portfolio include: Tweed Distillate Infused Bursting with flavour, Tweed Distillate Inf used Pre-Rolls are available in two new flavours - Black Cherry Chronic and Outlandish Orange. Black Cherry Chronic is a high-THC Sativa that provides a perfect blend of sweet and tart for a robust flavour and 33-39% THC. Outlandish Orange is a high-THCSativa that delivers a bright and zesty burst of flavour with 33-39% THC. Tweed Infusion Black Cherry Chronic and OutlandishOrange are available in 5x0.35g pre-roll packages. 7ACRES Burners 7ACRES Burners are designed to be the G.O.A.T of the pre-roll. Small batch grown with thoughtfully selected flavourful genetics comprised of a cross between Sour Dubble and Tahoe Alien to create Alien Rock Candy. Offered in a 3x0.7g format with 26 - 32% THC, these Burners are designed to deliver a slow and consistent burn. The unique filter design serves to optimize airflow enabling a smoother smoke to ensure the flavour of the true craft flower can be fully enjoyed. Spectrum Red No 1 Spectrum Red No 1 pre-rolls emit a fruity and gassy aroma and flavour profile due to the product's primary terpenes Terpinolene, Caryophyllene, and Limonene. With 22-28% THC, the 20 masterfully pre-rolled 0.5g joints are the first large pack offering in the Spectrum range. Spectrum Green Spectrum Green pre-rolls are an indica leaning hybrid strain with low amounts of THC with 2-8% and 10-16% CBD. This strain is well-suited for those who would like to try THC for the first time, as well as experienced consumers looking to add CBD to their routine. Spectrum Green pre-rolls come in a 20x0.5g pack, and some associate spicy, woody, lemon, or fuel flavours with this strain. Tweed and 7ACRES new pre-roll offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. Spectrum products are available for purchase online at spectrumtherapeutics.com. For more information, please visit Tweed, 7ACRES. Terpene amounts may vary on a per Lot basis due to the natural variability of cannabis plants.お知らせ • Aug 18+ 1 more updateCanopy Growth Corporation Announces Executive ChangesOn August 14, 2023, Thomas Stewart, who had been serving as the Canopy Growth Corporation’s Chief Accounting Officer and Principal Accounting Officer, transitioned to the position of Vice President, Finance of the Company and is no longer serving as the Company’s Principal Accounting Officer as of such date. Effective as of Mr. Stewart’s transition on August 14, 2023, Judy Hong, the Company’s Chief Financial Officer (“CFO”) and Principal Financial Officer, was designated as the Company’s Principal Accounting Officer. Judy Hong has served as the Company’s CFO since November 2021. Having joined the Company in December 2019 to lead Canopy’s Investor Relations team prior to being named CFO, Ms. Hong’s deep knowledge of the consumer packaged goods sector has been integral in shaping the Company’s overall commercial strategy and guiding the Company’s engagement with the financial community. Ms. Hong’s financial and capital markets experience was built during her over 20 years’ experience at Goldman Sachs & Co. Ms. Hong’s roles at Goldman Sachs & Co. included serving as a Managing Director, in the Global Investment Research Division, from 2013 until her departure in 2019. During this time, Ms. Hong covered the Beverage and Tobacco sectors in the Consumer Products and Retail team within Global Investment Research and has been ranked in The Wall Street Journal’s “Best on the Street.” Ms. Hong earned an MBA from New York University’s Stern School of Business and a BS in Communications from Cornell University. From September 2014 to January 2020, Ms. Hong served as a Treasurer on the Board of Directors of Bottomless Closet, a non-profit organization based in New York.株主還元CGCUS PharmaceuticalsUS 市場7D-2.9%-2.0%0.7%1Y-14.1%44.4%20.6%株主還元を見る業界別リターン: CGC過去 1 年間で44.4 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: CGCは、過去 1 年間で20.6 % のリターンを上げたUS市場を下回りました。価格変動Is CGC's price volatile compared to industry and market?CGC volatilityCGC Average Weekly Movement9.3%Pharmaceuticals Industry Average Movement9.3%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%安定した株価: CGC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CGCの 週次ボラティリティ は、過去 1 年間で14%から9%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a1,128Luc Mongeauwww.canopygrowth.comキャノピー・グロース・コーポレーションは、子会社とともに、カナダ、ドイツ、米国、およびその他の国々において、医療用および成人向けの大麻および大麻関連製品の生産、流通、販売を行っています。 同社は、「カンナビス」および「Storz & Bickel」の2つの事業セグメントを通じて事業を展開している。また、ベポライザーやアクセサリー、乾燥花やプレロール・ジョイント、オイル、ベイプ製品や飲料、ソフトジェルカプセルなどの抽出物・濃縮物、グミを含む大麻入り食品も提供している。 さらに、同社はEコマースショップ、医療用大麻のオンライン流通プラットフォーム、およびオンライン医療用大麻クリニックを運営している。同社は、「Tweed」、「7ACRES」、「Deep Space」、「HiWay」、「Maitri」、「Twd.」、 Spectrum Therapeutics、Canopy Medical、Abba Medix、Storz & Bickel、Wana、Claybourne、Apollo、Canada House、R’belle、LowKey、MTL Cannabis、DeeLish、DOJAといったブランド名で販売している。 同社は以前はTweed Marijuana Inc.という名称でしたが、2015年9月にCanopy Growth Corporationに社名を変更しました。Canopy Growth Corporationは、カナダのスミス・フォールズに本社を置いています。もっと見るCanopy Growth Corporation 基礎のまとめCanopy Growth の収益と売上を時価総額と比較するとどうか。CGC 基礎統計学時価総額US$411.53m収益（TTM）-US$185.72m売上高(TTM)US$201.04m2.0xP/Sレシオ-2.2xPER（株価収益率CGC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CGC 損益計算書（TTM）収益CA$284.60m売上原価CA$205.06m売上総利益CA$79.55mその他の費用CA$342.46m収益-CA$262.91m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.62グロス・マージン27.95%純利益率-92.38%有利子負債／自己資本比率33.5%CGC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 14:55終値2026/07/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Canopy Growth Corporation 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkJesse PytlakATB Cormark Historical (Cormark Securities)17 その他のアナリストを表示
お知らせ • Jul 08Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026.
Reported Earnings • Jun 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: CA$0.88 loss per share (improved from CA$5.62 loss in FY 2025). Revenue: CA$284.6m (up 5.8% from FY 2025). Net loss: CA$262.9m (loss narrowed 56% from FY 2025). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 86%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • May 29Canopy Growth Corporation Relaunches Tweed Brand in Germany with New Mtl Cannabis Strain LineupCanopy Growth Corporation announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp., a wholly-owned subsidiary of the Company. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 2025. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.
お知らせ • May 16Canopy Growth Corporation to Report Q4, 2026 Results on Jun 15, 2026Canopy Growth Corporation announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jun 15, 2026
お知らせ • May 09Canopy Growth Corporation and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsCanopy Growth Corporation and Spectrum Therapeutics announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. Together, these innovations support improved patient adherence and stronger clinical alignment. Daytime Formulations: Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack. Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack. Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack. Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations: Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack. A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack. Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May.
Seeking Alpha • Apr 23Canopy Growth Rallies On Renewed Hope Of Cannabis ReschedulingSummary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
お知らせ • Jul 08Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026Canopy Growth Corporation, Annual General Meeting, Sep 25, 2026.
Reported Earnings • Jun 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: CA$0.88 loss per share (improved from CA$5.62 loss in FY 2025). Revenue: CA$284.6m (up 5.8% from FY 2025). Net loss: CA$262.9m (loss narrowed 56% from FY 2025). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 86%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • May 29Canopy Growth Corporation Relaunches Tweed Brand in Germany with New Mtl Cannabis Strain LineupCanopy Growth Corporation announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp., a wholly-owned subsidiary of the Company. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 2025. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.
お知らせ • May 16Canopy Growth Corporation to Report Q4, 2026 Results on Jun 15, 2026Canopy Growth Corporation announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jun 15, 2026
お知らせ • May 09Canopy Growth Corporation and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsCanopy Growth Corporation and Spectrum Therapeutics announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. Together, these innovations support improved patient adherence and stronger clinical alignment. Daytime Formulations: Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack. Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack. Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack. Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations: Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack. A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack. Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May.
Seeking Alpha • Apr 23Canopy Growth Rallies On Renewed Hope Of Cannabis ReschedulingSummary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
New Risk • Apr 04New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$10.0k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$130m net loss in 2 years). Significant insider selling over the past 3 months (US$10.0k sold).
お知らせ • Mar 31Canopy Growth Corporation Unveils Deelish Cannabis Brand With High THC At Everyday PriceCanopy Growth Corporation announced Deelish, a new cannabis brand built for the everyday consumer with an everyday price. Deelish is Canopy Growth's newest brand, delivering high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish rotates its genetic lineup regularly, giving consumers access to a curated range of cultivars over time. Deelish launched with four SKUs across formats: Pretty Sweet Sativa 28g Whole Flower | 27-33% THC, Pretty Sweet Sativa 2x1g Pre-roll Joints | 26-32% THC, Pretty Chill Indica 28g Whole Flower | 27-33% THC, Pretty Chill Indica 2x1g Pre-roll Joints | 26-32% THC. Now available at select stores across Ontario and Alberta.
お知らせ • Feb 14Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million.Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $19.266745 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 18,705,578 Price\Range: $1.03
Reported Earnings • Feb 07Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: CA$0.18 loss per share (improved from CA$1.11 loss in 3Q 2025). Revenue: CA$74.5m (flat on 3Q 2025). Net loss: CA$62.6m (loss narrowed 49% from 3Q 2025). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • Jan 23Canopy Growth Corporation to Report Q3, 2026 Results on Feb 06, 2026Canopy Growth Corporation announced that they will report Q3, 2026 results Pre-Market on Feb 06, 2026
お知らせ • Dec 15Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million.Canopy Growth Corporation (TSX:WEED) entered into an arrangement agreement to acquire MTL Cannabis Corp. (CNSX:MTLC) for approximately CAD 120 million on December 14, 2025. Canopy Growth to acquire all of the issued and outstanding common shares in the capital of MTL on the basis of 0.32 of a common share of Canopy Growth (each whole share, a “Canopy Growth Share”) and CAD 0.144 in cash for each MTL Share, or approximately 38 million Canopy Growth Shares and CAD 17 million in cash in the aggregate. Pursuant to the Arrangement, each MC Shareholder will irrevocably, finally and fully release MTL, Canopy Growth and their respective affiliates from any and all obligations owing to such MC Shareholder pursuant to the Share Exchange Agreement, including for greater certainty, each MC Shareholder’s entitlement to anti-dilution rights pursuant to the Share Exchange Agreement (the “Release”) in exchange for such MC Shareholder’s pro rata entitlement to up to 2,956,391 (subject to reduction in certain circumstances) Canopy Growth Shares to be issued to the MC Shareholders pursuant to the Arrangement. The. Arrangement Agreement provides that a termination fee of CAD 4 million (the “Termination Fee”) will be payable by MTL upon termination of the Arrangement Agreement. Haywood Securities Inc. provided the MTL Cannabis Special Committee with an opinion that, as of December 14, 2025 and based upon and subject to the various assumptions, limitations, qualifications and other matters set forth in such opinion, the consideration to be received by the MTL Shareholders pursuant to the Transaction is fair, from a financial point of view, to MTL Shareholders. The Transaction was unanimously approved by the Board of Directors of Canopy Growth, as well as the Board of Directors of MTL Cannabis (with conflicted directors abstaining), following the unanimous recommendation of a special committee of the MTL Board of Directors (the “MTL Special Committee”). The MTL Special Committee and the Board of Directors unanimously recommended that MTL Shareholders vote in favour of the Transaction after determining the Transaction is fair to the MTL Shareholders and is in the best interests of MTL Cannabis. The Arrangement is subject to the conditions set forth in the Arrangement Agreement, including, among others: (i) approval by the Supreme Court of British Columbia (the “Court”) at a hearing upon the procedural and substantive fairness of the terms and conditions of the Arrangement; (ii) any approvals required under the Competition Act (Canada); and (iii) approval by the shareholders of MTL as required by applicable corporate and securities laws. The shareholders of MTL will be asked to vote on a resolution (the “Arrangement Resolution”) to, among other things, approve the Arrangement at a shareholder meeting to be called for such purpose, certain regulatory approvals, conditional approval of the Toronto Stock Exchange will have been obtained, including in respect of the listing and posting for trading of the Canopy Growth Shares issued as consideration for MTL Shares pursuant to the Arrangement and the MC Shareholder Consideration. Special meeting of MTL shareholders is expected to occur in February 2026, Expected closing by the end of February 2026. Jonathan Sherman of Cassels Brock& Blackwell LLP acted as legal advisor to Canopy Growth Corporation, Daniel Everall?of Farris LLP acted as legal advisor to MTL, Canaccord Genuity Corp. is acting as exclusive financial advisor to Canopy Growth. Paul Hastings LLP are acting as legal counsel to the Company, Haywood Securities Inc. is acting as exclusive financial advisor to the MTL Special Committee and provided a fairness opinion to the MTL Special Committee.
New Risk • Dec 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (180% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$50m net loss next year).
お知らせ • Dec 04Canopy Growth Corporation Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape SegmentCanopy Growth Corporation announced the national launch of Claybourne Gassers, a new lineup of All-in-One (AIO) vapes featuring liquid diamonds. The launch marks Claybourne's entry into Canada's vape category, building on its leadership in high potency infused products. The Claybourne Gassers collection includes three0.95g liquid diamondvapes: Infused Grape Gasolina (Indica): grape, diesel, pungent; Infused Blue Dream (Sativa): berry, blueberry, sweet; Infused Lemon Cherry G (Hybrid): lemon, cherry, sweet. Each vape contains 92-98% THC, a digital display, variable voltage, and anti-burn, anti-clog technology, all housed in a rechargeable USB-C palm-style format engineered for consistency and clean performance. Alongside Gassers, Claybourne Frosted Flyers are also launching in a new variety 8-pack (8x0.35g) featuring top-selling strains Grape Gasolina (Indica), Blue Dream (Sativa), and a mixed Berry Pack (Hybrid) with a combination of both strains. Each variety pack offers 33-36% THC in a convenient 0.35g format delivering Claybourne's signature potency and flavour. Claybourne Gassers and Claybourne Frosted Flyers variety 8-pack infused pre-rolls are now available at licensed retail stores and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.
お知らせ • Nov 19Canopy Growth Corporation Expands Spectrum Therapeutics Portfolio in Australia with New SoftgelsCanopy Growth Corporation has expanded its Spectrum Therapeutics portfolio in Australia with the availability of new softgel capsules, further enhancing the Company's medical cannabis offerings in the region. The formats include Spectrum Yellow Cannabis Oil Softgels (CBD 20mg), Spectrum Red Cannabis Oil Softgels (THC 10mg), and Spectrum Blue Cannabis Oil Softgels (Balanced THC 2.5mg: CBD 3.75mg). These softgels complement Spectrum Therapeutics' existing oils and flower, as well as flower products from Tweed, 7ACRES, and TWD already available to Australian patients. As Australia's medical cannabis market continues to mature, expanding Spectrum Therapeutics' portfolio further strengthens Canopy Growth's presence in the region.
Reported Earnings • Nov 09Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2026 results: CA$0.006 loss per share (improved from CA$1.52 loss in 2Q 2025). Revenue: CA$66.7m (up 5.9% from 2Q 2025). Net loss: CA$1.64m (loss narrowed 99% from 2Q 2025). Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) exceeded analyst estimates by 94%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • Oct 24Canopy Growth Corporation to Report Q2, 2026 Results on Nov 07, 2025Canopy Growth Corporation announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Nov 07, 2025
お知らせ • Oct 14Canopy Growth Corporation Announces Executive AppointmentsCanopy Growth Corporation at its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025, approved the election of Shan Atkins to serve as directors of the Company until the Company’s next annual shareholders meeting or until his or her successor is duly elected or appointed.
お知らせ • Sep 17Canopy Growth Appoints Tom Stewart as Chief Financial Officer, Effective September 17, 2025Canopy Growth Corporation announced that Tom Stewart has been appointed Chief Financial Officer, effective September 17, 2025. Mr. Stewart’s appointment supports the continued execution of Canopy Growth’s fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progress already underway to strengthen the Company’s balance sheet, Mr. Stewart’s leadership will play a key role in driving further performance in the quarters ahead. Mr. Stewart has served as Canopy Growth’s Interim Chief Financial Officer since July 2025 and has been a member of the Company’s senior finance leadership team since 2019. During this time, he has helped lead critical initiatives to stabilize the Company’s financial position, reduce expenses, and improve the Company’s liquidity position through disciplined debt repayments and capital raised via the Company’s “at-the-market” programs.
お知らせ • Aug 30+ 1 more updateCanopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million.Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $55.830365 million. Security Name: Common Stock Security Type: Common Stock Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,006,528 Price\Range: $1.328159 Transaction Features: At the Market Offering
Reported Earnings • Aug 10First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: CA$0.22 loss per share (improved from CA$1.63 loss in 1Q 2025). Revenue: CA$72.1m (up 8.9% from 1Q 2025). Net loss: CA$41.5m (loss narrowed 68% from 1Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • Aug 08Canopy Growth Corporation Appoints Margaret Shan Atkins to Its Board of Directors, Effective August 6, 2025Canopy Growth Corporation announced the appointment of Margaret Shan Atkins to its Board of Directors, effective August 6, 2025. Ms. Atkins brings extensive experience in retail strategy and operations, consumer goods, wholesale distribution, cybersecurity oversight, accounting and finance, and private investment in both the U.S. and Canada. Ms. Atkins is a former partner in the consumer and retail practice of international consultancy Bain & Company where she developed and executed strategic plans for major retail organizations. She also served as a C-suite executive at a Fortune 15 public retailer, where she led a multi-billion-dollar business unit. She presently serves on the boards of two U.S. public companies – Darden Restaurants (NYSE: DRI) and SpartanNash, where she chairs the audit committee at both companies and serves on the Governance and Nominating Committee at Darden and the Compensation Committee at SpartanNash. During the past five years, Ms. Atkins also served on the following public company boards of directors: Aurora Cannabis Inc., a Canadian cannabis company, from 2019 to 2023; SunOpta Inc., a North American manufacturer of natural and organic food products, from 2014 to 2019; LSC Communications Inc., a leading provider of long and short-run printing services to the book, catalog and magazine publishing industries, from 2016 to 2021.
お知らせ • Aug 05Canopy Growth Corporation Expands Global Medical Portfolio with Launch of 7ACRES in AustraliaCanopy Growth Corporation has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company’s medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES’ top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. The introduction of 7ACRES complements Canopy Growth’s existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth’s focus on building a scalable medical platform across international markets.
お知らせ • Jul 31Canopy Growth Corporation Announces Appointment of Miles Worne as Managing Director of European Markets, Effective August 11, 2025Canopy Growth Corporation announced the appointment of Miles Worne as Managing Director of European Markets, effective August 11, 2025. Mr. Worne will be responsible for leading the Company’s commercial operations and go-to-market execution across the region. His appointment reflects a strategic investment in Europe, where Canopy Growth aims to deepen its presence in established medical markets and build the capabilities needed to support long-term expansion as new opportunities emerge. Mr. Worne is an experienced commercial leader with over 20 years of global experience across the cannabis, healthcare, and consumer sectors. Most recently, he served as President of Curaleaf International, where he led the expansion of the company’s European medical cannabis operations. His background includes senior leadership roles in Europe, North America, and Asia at Glanbia Performance Nutrition and SlimFast International. Mr. Worne brings a strong track record of driving growth, building teams, and scaling businesses in regulated markets.
お知らせ • Jul 25Canopy Growth Corporation to Report Q1, 2026 Results on Aug 08, 2025Canopy Growth Corporation announced that they will report Q1, 2026 results Pre-Market on Aug 08, 2025
お知らせ • Jul 10Canopy Growth Corporation Launches Deep Space Infused Pre-RollsCanopy Growth Corporation has launched Deep Space Infused pre-rolls, a high-potency pre-roll joint innovation that brings the brand's signature boldness into one of the fastest-growing categories in cannabis. Deep Space Infused pre- rolls combine high-quality flower with liquid diamonds and THCA diamonds to deliver THC levels above 60%. Offered in a 3x0.5g format, the initial lineup includes two terpene-rich flavours: Milky Way Melon Infused and Big Bang Berry Infused. As Canopy's brand focused on bold formats and high-potency experiences, Deep Space pre-rolls are uniquely positioned to meet the needs of consumers seeking stronger, more flavour-forward products. This launch follows recent Deep Spacebeverage and gummy innovations introduced earlier this year, and builds on the momentum of Claybourne's Frosted Flyers, which have continued to gain traction since launching in November 2024. Together, these offerings strengthen Canopy's position in infused formats and reflect the Company's commitment to targeted innovation in high-growth segments. Deep Space Infused pre -rolls are now available at licensed in-store and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.
お知らせ • Jul 09+ 1 more updateCanopy Growth Corporation Appoints CFO ChangesCanopy Growth Corporation announced the appointment of Tom Stewart as Interim Chief Financial Officer, effective immediately. Mr. Stewart succeeds Judy Hong, who served as Canopy Growth’s Chief Financial Officer since April 2022. During her tenure, Ms. Hong played a key role in improving the Company’s capital structure and significantly strengthening its financial position. Canopy Growth thanks Ms. Hong for her leadership and support of its strategic vision. Mr. Stewart is an accomplished finance executive with over 20 years of experience with public companies, including accounting, reporting, FP&A, and operational finance. He joined Canopy Growth in 2019 as Chief Accounting Officer, following 10 years in increasingly senior finance roles at Constellation Brands Inc. Mr. Stewart began his career at PricewaterhouseCoopers and is a Certified Public Accountant in the state of New York. Mr. Stewart’s appointment is part of the Company’s continued execution of its Fiscal 2026 strategy, which includes a sharpened focus on operational efficiency, disciplined capital management, and building a sustainable, performance-led business. His background in performance-driven consumer packaged goods finance and accounting makes him well-suited to support Canopy Growth’s financial and operational priorities in this next phase.
New Risk • Jul 01New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$71k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (146% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$177m). Currently unprofitable and not forecast to become profitable over next 2 years (CA$93m net loss in 2 years). Significant insider selling over the past 3 months (US$71k sold).
Recent Insider Transactions • Jun 20CFO & Principal Accounting Officer recently sold US$57k worth of stockOn the 16th of June, Judy Hong sold around 39k shares on-market at roughly US$1.47 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Judy has been a net seller over the last 12 months, reducing personal holdings by US$365k.
Reported Earnings • May 30Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: CA$5.62 loss per share. Revenue: CA$269.0m (down 9.5% from FY 2024). Net loss: CA$604.1m (loss widened 25% from FY 2024). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 27%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$177m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$177m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$106m net loss in 2 years).
お知らせ • May 06Canopy Growth Corporation Drives Innovation in High-Demand Segments with Latest Product LaunchesCanopy Growth Corporation has launched a series of product innovations targeting Canada's fastest-growing adult-use categories. The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This fresh lineup strengthens Canopy's presence in core formats and is backed by its brands. Tweed and 7ACRES anchor the portfolio with consistent, high-quality offerings, Claybourne builds on strong momentum in key markets, and Deep Space returns to the edibles category. Canopy Growth's latest introductions include: Advanced All-in-One Vapes with CCELL Technology: Canopy Growth is introducing CCELL's newest all-in-one ("AIO") vape technology to the Canada adult-use market through Tweed and 7ACRES. The advanced hardware includes a built-in display screen for variable voltage and battery life, offering a more functional and enhanced experience. This launch supports Canopy's strategy to deepen its presence in high demand vape formats. Tweed is launching three new 0.95g liquid diamond AIO vapes: Gorilla Berry Grape, Blood Orange Kush, and Kush Mints. 7ACRES is introducing 0.95g AIO vapes in Blue Dream and Jack Haze with a curated blend of live resin and liquid diamonds. New Flower Genetics from Tweed Tweed is releasing two new high-THC cultivars - Sour Sucker Mints and Blood Orange Kush, both testing above 28% THC. Sour Sucker Mints crosses Ultra Sour and Kush Mints offering a sharp citrus bite, balanced by sweet mint and gassy undertones. Recent harvests are testing between 3.25-4% total terpenes. Expanded Offerings in Pre-rolls and Infused PRJs: Pre-rolls remain one of the most in-demand formats in Canada's adult-use market, and Canopy Growth is expanding its offerings to meet evolving consumer preferences. Claybourne Frosted Flyers, Canada's fastest growing pre-roll brand,3 is adding two new flavours: Watermelon Z and Infused Super Sour Apple -and a new 5x0.5g format alongside the original 3x0.5g offering. Tweed expands its Quickies line with Sour Sucker Mints and blood Orange Kush in a 10x0.35g format. 7ACRES is introducing 3x0.5g infused Live ResinBlue Dream and Jack Haze pre-rolls. In addition, 7ACRES is launching live resin-infused hash in Blue Dream and Jack Hazing - offering another format option for high-THC consumers. Deep Space Expands into Gummies: Deep Space, known for its strong following in cannabis beverages, is re-entering the edibles category with ario of gummies - building on the brand's high-potency positioning. Sour Pulsar Peach, Sour Strawberry void, and Blue Sourberry. Each pack contains one10mg THC gummy and naturally occurring caffeine, offering a flavour-forward functional experience. These new products from Canopy Growth are now available at licensed in-store and online cannabis retailers in select regions across Canada, including the Spectrum Therapeutics online store for registered medical consumers.
New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$107m net loss in 2 years).
Seeking Alpha • Apr 22Canopy Growth: Zombie Financials As Delisting Threat LoomsSummary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
お知らせ • Apr 05Robbins LLP Informs Stockholders of the Canopy Growth Corporation Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Canopy Growth Corporation securities between May 30, 2024 and February 6, 2025. Canopy, together with its subsidiaries, produces, distributes, and sells cannabis and hemp-based products for recreational and medical purposes. The Allegations: Robbins LLP is Investigating Allegations that Canopy Growth Corporation (CGC) Misled Investors Regarding its Cost Reduction Measures According to the complaint, during the class period, defendants failed to disclose that: (i) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (ii) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company's gross margins and overall financial results; and (iii) accordingly, defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same. On February 7, 2025, Canopy announced disappointing financial results "primarily due to the incremental costs related to the Claybourne infused pre-roll launch in Canada, and an increase in indirect costs of Storz & Bickel vaporizer devices.
お知らせ • Apr 02Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis BrandCanopy Growth Corporation has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation - featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a regular basis based on patient needs, preferences, and feedback. The strains which generate the most positive and consistent customer feedback will remain in market, while others will be phased out to make way for new genetics through a process of constant enhancement. This approach will help Spectrum Therapeutics consistently deliver new, premium quality strains to the medical cannabis market in Canada. The first release under the Spectrum Reserve brand features four flower strains, each selected for the combination of their potency and terpene profile: Power Plant x Super Silver Haze (Indica, 22-25% THC): A rich, woody and earthy aroma, with a sharp, peppery taste and 2.21% total terpenes. Grape Star x Golden Lemons (Sativa, 22-25% THC: With a dank white grape aroma, this strain features 1.77% total terpenes, offering a smooth, uplifting experience. Malawi x Kosher Tangie (Hybrid, 27-30% THC): A complex citrus and chocolate flavour profile, complemented by a pungent, earthy aroma, with 2.59% total terpenes. Raspberry Parfait (Sativa-Dominant Hybrid, 22-27% THC): With 2.59% total ter Penes, this strain features aum, berry, and violet aroma for a rich and flavorful experience.
Seeking Alpha • Mar 30Cannabis Investors Should Sell Canopy GrowthSummary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
お知らせ • Mar 19Canopy Growth Corporation to Report Q4, 2025 Results on May 30, 2025Canopy Growth Corporation announced that they will report Q4, 2025 results on May 30, 2025
お知らせ • Mar 01+ 1 more updateCanopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million.Canopy Growth Corporation has completed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,747,064 Price\Range: $7.116078 Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,058,788 Price\Range: $5.653206 Security Name: Common Stock Security Type: Common Stock Securities Offered: 22,713,177 Price\Range: $3.594743 Transaction Features: At the Market Offering
Seeking Alpha • Feb 17Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains WeakSummary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Reported Earnings • Feb 07Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: CA$1.11 loss per share (improved from CA$2.78 loss in 3Q 2024). Revenue: CA$74.8m (down 4.8% from 3Q 2024). Net loss: CA$121.9m (loss narrowed 47% from 3Q 2024). Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 95%. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.
Seeking Alpha • Feb 06Canopy Growth: Still A Disaster Heading Into Fiscal Q3 ResultsSummary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
お知らせ • Jan 24Canopy Growth Corporation to Report Q3, 2025 Results on Feb 07, 2025Canopy Growth Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 07, 2025
Seeking Alpha • Jan 22Crashing Canopy Growth Is Still Not A BuySummary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$124m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change).
Seeking Alpha • Jan 11Canopy Growth Remains Undervalued Amidst Cannabis Sector UncertaintySummary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
お知らせ • Dec 05Canopy Growth Corporation Launches Two Holiday-Inspired Cannabis Products from Tweed, Including A Sugar-Free Cranberry Ginger Ale and Tweed Snowtorious 91K FlowerCanopy Growth Corporation announced the launch of two holiday-inspired cannabis products from Tweed, including a sugar-free Cranberry Ginger Ale and Tweed Snowtorious 91K flower, to bring a little extra cheer to the season's festivities. Tweed Cranberry Ginger Ale pays homage to a classic Canadian favourite, reimagined for the holidays. Enjoy this sugar-free cannabis beverage with 10mg of THC. Tweed Snowtorious 91 K. This holiday-inspired flower is a true seasonal delight. Tweed Snowtorious91K is a bold and frosty indica with minty and diesel aromas. It's a cross between popular cultivars Kush Mints (Animal Mints x Bubba Kush) and 91K (Chemdawg 91 x OG Captain Krypt), set to bring some holiday magic to any winter scene. If you're looking for a stocking stuffer or want something personal to celebrate the end of a long year, 7ACRES Ultra Jack flower and Claybourne Frosted Flyers Infused Pre-Rolls offer a high quality and premium experience for any enthusiast. 7ACRES Ultra Jack. With aromas that evoke the holidays, 7ACRES Ultra Jack is a terpene rich sativa-dominant hybrid created by crossing cultivars Ultra Sour with renowned 7ACRES Jack Haze. Experience a citrus kick with undertones of earthy spice. Claybourne Froster Flyers. Experience some California love this holiday season with Claybourne's Frosted Flyers infused pre-rolls. New in Canada, Claybourne Frosted Flyers offer high potency and nonstop flavour from start to finish and are available in Blue Dream, Strawberry Cough, Pineapple Express, Grape Gasolina, and Banana OG as part of a 1.5g 3-pack or a 5 x 0.5g (2.5g total) Variety Pack. These offerings from Canopy Growth will be available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions in addition to the Spectrum Therapeutics online store for authorized medical cannabis consumers.
お知らせ • Nov 26+ 1 more updateCanopy Growth Corporation Appoints Luc Mongeau as Chief Executive Officer, Effective January 6, 2025Canopy Growth Corporation announced that the company's board of directors has named current Board member and CPG-veteran, Mr. Luc Mongeau, as the next Chief Executive Officer (CEO) of the company effective January 6, 2025. A seasoned executive with broad CPG experience, Mr. Mongeau has most recently served as the CEO of North America's leading e-commerce provider for residential and commercial furniture. He has previously held the role of President for Weston Foods as well as President of Mars Petcare North America. Since joining the Board as an observer in early 2023 and as a Board member in February 2024, Mr. Mongeau has played a key role in shaping the company's strategy. This has included a focus on driving asset-light expansion across canopy Growth's core markets, as well as actions to achieve near term profitability as the company meets the vast opportunities presented by the global cannabis market. Mr. Mongeau will remain a member of the Board in his new role as CEO, and to support an efficient transition, Mr. Klein will continue in his role as CEO and a director on the Board until the effective date of Mr. Mongeau's appointment as CEO on January 6, 2025. With a proven track record of leading and elevating organizations, Mr. Mongeau joins Canopy Growth with over 25 years' experience as a senior executive. He has demonstrated expertise in marketing, sales, supply chain operations, and M&A. Most recently as the CEO of ESolutions Furniture, formerly Bestar-Bush, Mr. Mongeau led the transformation of the business to deepen its share of the highly competitive digital commerce furniture industry. This included implementing a new approach to design and sourcing, reconfiguring the North American manufacturing network, and enhancing the company's global supply chain. Prior to this, during Mr. Mongeau's five-year tenure as President of Weston Foods, he spearheaded the strategic realignment and end-to-end operational leadership of the $2 billion North American bakery, overseeing a team of over 6,000 employees across 40 facilities. He directed the development of commercial strategies across branded and private label categories for major North American retailers and managed the sale of Weston Foods. Additionally, in his role as President of Mars Petcare North America, Mr. Mongeau provided strategic and operational leadership to a $3 billion North American organization with more than 3,000 employees, 27 manufacturing sites, and three distinct operating units within both branded and private label categories. Mr. Mongeau holds a Bachelor of Science from the Université de Sherbrooke and an MBA from the Ivey School of Business at Western University. He has also completed executive education at Harvard Business School.
お知らせ • Nov 21Canopy Growth Launches Claybourne Infused Pre-Rolls in CanadaCanopy Growth Corporation announced through an exclusive licensing agreement the launch of California grown Claybourne brand in Canada. This initial launch brings Claybourne's Frosted Flyers Infused Pre-Rolls to Canadian medical and adult-use consumers in five distinct offerings, Blue Dream, Strawberry Cough, Pineapple Express, Grape Gasolina and Banana OG. Each Frosted Flyer is high potency and packed with nonstop flavor from start to finish. Claybourne Frosted Flyers Infused Pre-Rolls offer higher potency, unrivaled smokability and consistent flavour. This is achieved through a multi-step innovative, artisanal and hand-made approach to crafting the final product through: Diamond Frosting: a unique, flavourless THCa coating on the outside of the joint provides added potency and contributes to a consistent, full flower flavour experience from beginning to end. Liquid Diamond Infusion: added concentrated THC in the form of diamonds. Terpene Enhanced: an additional infusion of natural terpenes to help accent the bold flavours of your favourite flower. Premium Indoor Full Nug Flower: made with 100% indoor cultivated flower. Claybourne Frosted Flyers Infused Pre-Rolls will be available in five offerings – each as part of a 1.5G 3-pack, as well as a 5 x 0.5G (2.5G total) Variety Pack. Blue Dream 3x0.5g pack (sativa): 42-48% THC (myrcene, pinene and caryophyllene), Strawberry Cough 3x0.5g pack (sativa): 42-48% THC (myrcene, pinene and caryophyllene), Pineapple Express 3x0.5g pack (hybrid): 42-48% THC (myrcene, pinene and caryophyllene), Grape Gasolina 3x0.5g pack (indica): 42-48% THC (myrcene, linalool and caryophyllene), Banana OG 3x0.5g pack (indica): 42-48% THC (limonene, myrcene and caryophyllene), Variety Pack 5x0.5g pack (Sa-Hybri-Ca): 36-40% THC. Through a combination of homegrown innovation and collaborations with the biggest brands in cannabis, like Claybourne, Canopy Growth is strategically positioned to further advance its leadership in this category. New Claybourne pre-roll offerings will be available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions in addition to the Spectrum Therapeutics online store for authorized medical cannabis consumers.
Seeking Alpha • Nov 10Avoid Canopy GrowthSummary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Reported Earnings • Nov 10Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: CA$1.52 loss per share (improved from CA$1.86 loss in 2Q 2024). Revenue: CA$63.0m (down 9.5% from 2Q 2024). Net loss: CA$131.6m (loss narrowed 1.4% from 2Q 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 192%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Seeking Alpha • Oct 05Canopy Growth: Weak Fundamentals And Growth Acceleration ChallengesSummary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Recent Insider Transactions • Aug 27Insider recently sold US$103k worth of stockOn the 22nd of August, Christelle Gedeon sold around 17k shares on-market at roughly US$6.14 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$388k more than they bought in the last 12 months.
Seeking Alpha • Aug 27Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End HighSummary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
お知らせ • Aug 16David Klein Announces to Retire as CEO of Canopy Growth CorporationCanopy Growth Corporation announced that Mr. David Klein, CEO of the company, will be retiring at the conclusion of the Company's current fiscal year ending March 31, 2025. Until this date or such time that a successor is named, Mr. Klein will continue in his role as CEO and as a member of the Company's Board of Directors to advance Canopy Growth's strategic objectives including profitability and ensure an effective transition. The Board is in the process of securing a globally recognized search firm to initiate a comprehensive CEO selection process focused on identifying a candidate with the right mix of skills, experience, and expertise to lead the Company in its next chapter of growth. Since joining Canopy Growth as CEO in January of 2020, Mr. Klein successfully led the transformation and development of Canopy Growth to meet the vast opportunities presented by the global cannabis market. Under his leadership, the Company established a foundation for multi-market cannabis leadership through its transformation to an asset light model in Canada and across a range of international markets, including Germany. In addition, Mr. Klein oversaw the launch and advancement of Canopy USA as a first of its kind structure to offer the Company's shareholders unique exposure to the rapid growth and opportunity presented by the U.S. cannabis market ahead of federal permissibility.
Reported Earnings • Aug 11First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: CA$1.63 loss per share (further deteriorated from CA$0.12 loss in 1Q 2024). Revenue: CA$66.2m (down 13% from 1Q 2024). Net loss: CA$129.2m (loss widened CA$122.4m from 1Q 2024). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • Aug 06Canopy Growth Corporation to Report Q2, 2025 Results on Nov 12, 2024Canopy Growth Corporation announced that they will report Q2, 2025 results on Nov 12, 2024
お知らせ • Jul 26Canopy Growth Corporation to Report Q1, 2025 Results on Aug 09, 2024Canopy Growth Corporation announced that they will report Q1, 2025 results Pre-Market on Aug 09, 2024
お知らせ • Jul 09Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024.
Buy Or Sell Opportunity • Jul 01Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$6.39. The fair value is estimated to be US$8.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has grown by 12%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 44% per annum over the same time period.
Buy Or Sell Opportunity • Jun 27Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to US$6.63. The fair value is estimated to be US$5.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 21% over the last 3 years. Earnings per share has grown by 12%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 69% per annum over the same time period.
Seeking Alpha • Jun 17Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
お知らせ • Jun 08Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million.Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Jun 04Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: CA$6.22 loss per share (improved from CA$70.69 loss in FY 2023). Revenue: CA$297.1m (down 26% from FY 2023). Net loss: CA$465.2m (loss narrowed 86% from FY 2023). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in the US.
Seeking Alpha • Jun 03Canopy Growth: Another Ugly Cannabis ReportSummary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
お知らせ • May 18Canopy Growth Corporation to Report Q4, 2024 Results on May 30, 2024Canopy Growth Corporation announced that they will report Q4, 2024 results Pre-Market on May 30, 2024
New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).
Seeking Alpha • Apr 26Canopy Growth Set For U.S. Cannabis MarketsSummary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Board Change • Apr 23Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chair of the Board Dave Lazzarato was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 20Canopy Growth Corporation Announces Board and Committee ChangesCanopy Growth Corporation announced in connection with the termination of the Investor Rights Agreement and subsequent to the Note Exchange, on April 18, 2024, Garth Hankinson, Judy Schmeling and James Sabia (collectively, the CBG Nominees) each provided notice to the Company of his or her decision to resign from the Board effective immediately (the CBI Resignations). Each of the CBG Nominees had been a nominee of the CBG Group under the Investor Rights Agreement. Ms. Schmeling had served as Chair of the Board and as a member of the Audit Committee of the Board, and Mr. Sabia had served as a member of the Corporate Governance, Compensation and Nominating Committee of the Board (the CGCN Committee). None of the CBI Resignations were the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Following the CBI Resignations, the Board is now comprised of: David Lazzarato (Chair of the Board, Member of the Audit Committee and Member of the CGCN Committee); Willy Kruh (Director and Chair of the Audit Committee); Theresa Yanofsky (Director, Chair of the CGCN Committee and Member of the Audit Committee); Luc Mongeau (Director and Member of the CGCN Committee); and David Klein (Chief Executive Officer and Director).
New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).
Seeking Alpha • Mar 22Canopy Growth Is Climbing, But It Won't LastSummary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
お知らせ • Feb 22Canopy Growth Launches New Pre-Rolls from 7Acres and HiwayCanopy Growth Corporation announced the introduction of five new pre-roll products across the Company's adult-use cannabis portfolio from brands 7ACRES and Hiway. 7ACRES Smooth Burners 2x0.7g cannabis pre-rolls feature a hybrid designed to deliver the smoothest and slowest burn. Smooth Burners derive from GMO Zkittlez x Funky Zktlz lineage and feature 22-28% THC. 7ACRES Smooth Burners 0.7g are built for a slow burning and smooth smoking experience a unique filter design to optimize airflow and ensure a smooth smoke, 7ACRES Smooth Burners are also relightable and crafted for those on the go who may want to reenjoy later. For those looking for high-quality in a value package, Hiway Water Hash Infused pre-rolls 3x0.5g deliver the goods. Developed for high THC, with a flavourful selection of blended indica or sativa cultivars. With nothing additional added, Hiway Water Hash Infused pre-rolls offer pure dried cannabis and bubble hash evenly rolled for a smooth burn. For those looking for variety, convenience, and a large pack size, Hiway Roadies 20x0.35g are offered in sativa and indica with both options coming in with 18-24% THC. Strains may change from lot to lot allowing consumers to try a variety of batches offering an original, new, and pre-roll experience. With high THC and minimal CBD, Hiway Roadies 20x0.35g are the ultimate in high value.
Reported Earnings • Feb 11Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: CA$2.78 loss per share. Revenue: CA$78.5m (down 7.5% from 3Q 2023). Net loss: CA$230.3m (loss widened 3.8% from 3Q 2023). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • Feb 10Canopy Growth Corporation Announces Board ChangesCanopy Growth Corporation announced that Robert L. Hanson has resigned from it's Board of Directors, effective as of February 6, 2024. As part of the advancement of Canopy USA, and the expected departure of CBI appointed Board members following the creation of the Exchangeable Shares, Canopy Growth announced the appointment of two new Board members, Willy Kruh and Luc Mongeau, to the Company's Board, effective as of February 7, 2024. Willy Kruh – Director, Member of the Audit Committee: Willy J. Kruh CPA, CA, MBA, is a retired Partner and Global (and Canadian) Chairman of Consumer and Retail at KPMG LLP, with over 35 years of experience. As a recognized and trusted, advisor, consultant, and auditor, Willy has been instrumental in shaping the financial landscape of leading consumer packaged goods ("CPG"), retail, food, and beverage, multinational corporations, offering strategic guidance and invaluable insights to industry leaders in North America and globally. Willy brings wide ranging financial as well as consumer and retail industry experience to the Board.Luc Mongeau – Director, Member of the Corporate Governance, Compensation & Nominating Committee: Luc Mongeau is a seasoned executive with over 25 years of experience spearheading multi-billion-dollar CPG companies throughout North America, including Weston Foods, Mars and Mars Petcare. An established leader with a demonstrated track record of marketing and sales agility, Luc has consistently delivered transformative growth and operational excellence in brand led businesses. Luc brings his extensive experience in business transformation and strategic leadership to the Board.
New Risk • Feb 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$51m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Significant insider selling over the past 3 months (US$94k sold).
お知らせ • Feb 08Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED) on February 7, 2024. KeyLeaf is now POS Biosciences Corp., a wholly owned subsidiary of Bioriginal Food & Science Corp. KeyLeaf Life Sciences will operate independently, guided by Jim Shields, the new Managing Director. Bioriginal Food & Science Corporation completed the acquisition of KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED) on February 7, 2024.
Seeking Alpha • Feb 06Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To ComeSummary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29Canopy Growth: Further Implosion Is Now A Matter Of When Not IfSummary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
お知らせ • Jan 24Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis PortfolioCanopy Growth Corporation announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. Tweed Lemon Meringue Pie flower: For consumers not wanting to compromise quality for quantity, Tweed Lemon Meringue Pie is being served up fresh in a large format 28g package. Packed with sativa whole cannabis flower which has been derived from the Lemon Skunk and Cookies `n' Cream lineage, it features terpenes a-Pinene, Myrcene and Limonene. Tweed's Lemon Meringue Pie boasts lemon, citrus and nutty vanilla aromas, is hang- dried, and comes in with a 23-29% THC range. Grown in Kincardine, Ontario facility and packaged with a Boveda humidity control pack to ensure freshness, this new flower offering is full of flavour just like lemon meringue should be. 7ACRES Jack Haze pre-rolls: 7ACRES Jack Haze pre-rolled joints are arriving in a 0.5gx14 large pack and feature the famous sativa- dominant cultivar with a unique combination of sweet citrus, crisp pine, and warm spice notes. With a range of 17-23% THC and a max CBD potency of 25%, 7ACRES Jack Haze was the result of a large- scale genetic selection program with the goal of finding this novel sativa expression. This phenotype stood out among the rest as it possessed both the sweet haze notes characteristic of a haze cultivar, along with a distinct spice aroma. Spectrum Reserve pre-rolls: Exclusive for medical cannabis customers, Spectrum Therapeutics is extending its Spectrum Reserve collection with Alien Breath and (GG#4 x Mendo Breath) pre-roll joints. Coming in a 0.5gx10 large pack of pre-rolls, this hybrid strain delivers a high 22-28% THC range. The flower's berry, fruity, nutty, sour, and chemical notes derive from its Alien Breath and (GG#4 x Mendo Breath) lineage and its terpenes include 3.5% -Caryophyllene, 6% D-Limonene, 6.5% Beta Myrcene, and 10% Pinene (Alpha & Beta). With consumer needs top of mind, Tweed has also introduced four new products featuring CBD and minor cannabinoids in both oil and softgel formats. Tweed CBD:CBG 4:1 Oil: A newly formulated cannabis oil arriving in a 30mL bottle, Tweed CBD:CBG 4:1 is designed to pair with well-being focused daily routines and provides 100 mg/g CBD and 25 mg/g CBG. Tweed CBD:CBG 6:1 Softgels: For those who prefer the convenience and portability of the softgel format, Tweed CBD:CBG 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBG. Tweed CBD:CBN 4:1 Oil: Coming in a 30mL oil format, the Tweed CBD:CBN 4:1 oil offering is designed to become part of a nightly routine and delivers 100 mg/g CBD and 25 mg/g CBN. Tweed CBD:CBN 6:1 Softgels: Another win for those who prefer the convenience of softgels, Tweed CBD:CBN 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBN.
お知らせ • Jan 18Canopy Growth Corporation announced that it expects to receive $35.000008 million in fundingCanopy Growth Corporation announced it has entered into subscription agreements of 8,158,510 units at issue price $4.29 per unit for gross proceeds of $35,000,007.9 on January 18, 2024. Each Unit will be comprised of one common share of the Company and one Series A Common Share purchase warrant or one Series B Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share from the Company at a price equal to $4.83. The Series A Warrants will be exercisable immediately following the closing of the Offering for a period of five years from such date and the Series B Warrants will be exercisable for a period commencing on the date that is six-months following the closing of the Offering and ending on the date that is five years following such date. The Company has also agreed to provide the Investors with customary registration rights. The closing of the private placement pursuant to the Subscription Agreements is expected to occur on or about January 19, 2024, subject to Toronto Stock Exchange approval and customary closing conditions
Seeking Alpha • Jan 14Avoid Canopy Growth After Failed Equity SaleSummary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha
お知らせ • Jan 13Canopy Growth Corporation to Report Q3, 2024 Results on Feb 09, 2024Canopy Growth Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Jan 09Canopy Growth Corporation announced that it expects to receive $30 million in fundingCanopy Growth Corporation announced a private placement of 6,993,007 units at a price of $4.29 per share for the gross proceeds of $30,000,000 on January 9, 2024. Each unit will be comprised of (a) one common share of the company and one series A Common Share purchase warrant or one Series B Common Share purchase warrant. Each warrant will entitle the holder to acquire one common share from the company at a price equal to $4.83. The transaction is expected to occur on or about January 10, 2024, subject to customary closing conditions.
お知らせ • Dec 19Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million on December 18, 2023.Inspirit Management Ltd completed the acquisition of This Works Products Limited from Canopy Growth Corporation (TSX:WEED) on December 18, 2023.
お知らせ • Nov 30Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD GummiesCanopy Growth Corporation Partnered with Marquee Brands Partners and Martha Stewart CBD unveiled a new line of need-based CBD gummies, broadening the brand's evolving wellness assortment. Martha Stewart CBD products provide consumers with convenient, plant-based solutions to help people feel their best all day, every day. The new line was developed in response to consumer demand for targeted solutions that address their most common needs: sleep, stress, and the discomfort of aches and soreness. Each product is formulated with higher levels of CBD and powerful co-active ingredients selected for their known efficacy. In partnership with Marquee Brands and Canopy Growth Corporation, a diversified cannabis and cannabinoid-based consumer product company, Martha's new solution-oriented formulations combine her signature elevated flavor profiles with Canopy Growth's unique consumer insights and continuous industry innovation. The result is three delicious, effective, and tailored new offerings: Sleep CBD Gummies: A berry medley with notes of Montmorency cherry, elderberry, and boysenberry. 25 mg CBD: 3 mg Melatonin. 60 ct - $59.99 MSRP. Chill CBD Gummies: A citrus-forward concoction of tangerine, yuzu, and pomelo 25 mg CBD: 50 mg L-Theanine. 60 ct- $59.99 MSRP; Extra Strength CBD Gummies: An orchard-inspired blend of pluot, apricot, and California red peaches; 30 mg CBD. 60 ct - $59.99 MSRP.
New Risk • Nov 24New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$107k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CA$520m). Currently unprofitable and not forecast to become profitable over next 3 years (CA$63m net loss in 3 years). Significant insider selling over the past 3 months (US$107k sold).
お知らせ • Nov 17Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and TweedCanopy Growth Corporation announced the addition of four new flower product offerings from iconic brands 7ACRES and Tweed just in time for the holiday season. New products rolling out under Canopy Growth's flower portfolio include: 7ACRES Holiday Taster Pack - The holidays are arriving early this year with the launch of two flavourful holiday-inspired flower harvests. 7ACRES Holiday Taster Pack (2x7g) 14g featuring strains Ultra Jolly Jack and Peppermint Krypt is now available for purchase. Ultra Jolly Jack is a Sativa-dominant cross of Jack Haze and Ultra Sour strain lineage, creating afestive aroma that features holiday spices alongside earthy and lemon undertones. Complementing Ultra Jolly Jack is the Indica-dominant hybrid Peppermint Krypt, with its sweet and spicy holiday aromas as well as creamy undertones thanks to the cross between frosty Kush Mints and 91K.Both strains feature a 24-30% THC range, are hang dried, and packaged with a Boveda pack to ensure freshness, making the 7ACRES Holiday Taster Pack a thoughtful gift for consumers looking for convenience, variety, and a high-quality experience. Tweed Gorilla Berry and Chemsicle: Given the pressures of the holiday season, Tweed is making it easy to unwind with two new whole flower offerings, Tweed Gorilla Berry and Tweed Chemsicle. Tweed Gorilla Berry is an Indica whole cannabis flower born from the Frosted Kush x Gorilla and Triangle Kush x Blueberry lineage, and features terpenes Terpinolene, ß-Caryophyllene, and ß- Pinene. Bringing forth the sweetness of the holidays, Tweed Gorilla Berry boasts berry and citrus flavours, a gassy aroma, and a 28-34% THC range, making it a perfect stocking (or pipe) stuffer for those looking for full flavour and superior quality. If you're seeking more spice in the seasonal celebrations, Tweed's Chemiscle is a great choice as the Sativa whole flower offers a creamy, spicy, and earthy flavor and aroma. Derived from 91K and Chemdawg lineage, Chemiscle has a 24-30% THC range with terpenes including ß-Myrcene, ß- Pinene, -Pinene. Both strains are packaged with Boveda 2-way humidity control packs and come in 14g whole flower formats. 7ACRES and Tweed's new flower offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions.
New Risk • Nov 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$520m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$520m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$69m net loss in 3 years).
Reported Earnings • Nov 10Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: CA$0.19 loss per share (improved from CA$0.47 loss in 2Q 2023). Revenue: CA$69.6m (down 41% from 2Q 2023). Net loss: CA$133.4m (loss narrowed 40% from 2Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 163%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.
Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Garth Hankinson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 20Canopy Growth Corporation announced that it expects to receive $24.99312 million in fundingCanopy Growth Corporation announced a private placement and entered into into subscription agreements with certain institutional investors to issue 22,929,468 units at a price per Unit of $1.09 for the gross proceeds of $24,993,120.12 on September 18, 2023. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share from the Company at a price equal to $1.35 for a period of five years from the date of issuance. The closing of the private placement pursuant to the Subscription Agreements is expected to occur on or about September 19, 2023, subject to customary closing conditions. The Investors also hold an over-allotment option to acquire up to an additional 22,929,468 Units at a price per Unit of $1.09 for aggregate gross proceeds of $24,993,120.12 at the discretion of the Investors at any time on or before November 2, 2023 (the “Over-Allotment Option”).
お知らせ • Aug 23Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum TherapeuticsCanopy Growth Corporation announced the addition of five new pre-roll flower product offerings from iconic brands Tweed, 7ACRES, and for the first time, from Canopy Growth's medical cannabis company, Spectrum Therapeutics. New products rolling out under Canopy Growth's flower portfolio include: Tweed Distillate Infused Bursting with flavour, Tweed Distillate Inf used Pre-Rolls are available in two new flavours - Black Cherry Chronic and Outlandish Orange. Black Cherry Chronic is a high-THC Sativa that provides a perfect blend of sweet and tart for a robust flavour and 33-39% THC. Outlandish Orange is a high-THCSativa that delivers a bright and zesty burst of flavour with 33-39% THC. Tweed Infusion Black Cherry Chronic and OutlandishOrange are available in 5x0.35g pre-roll packages. 7ACRES Burners 7ACRES Burners are designed to be the G.O.A.T of the pre-roll. Small batch grown with thoughtfully selected flavourful genetics comprised of a cross between Sour Dubble and Tahoe Alien to create Alien Rock Candy. Offered in a 3x0.7g format with 26 - 32% THC, these Burners are designed to deliver a slow and consistent burn. The unique filter design serves to optimize airflow enabling a smoother smoke to ensure the flavour of the true craft flower can be fully enjoyed. Spectrum Red No 1 Spectrum Red No 1 pre-rolls emit a fruity and gassy aroma and flavour profile due to the product's primary terpenes Terpinolene, Caryophyllene, and Limonene. With 22-28% THC, the 20 masterfully pre-rolled 0.5g joints are the first large pack offering in the Spectrum range. Spectrum Green Spectrum Green pre-rolls are an indica leaning hybrid strain with low amounts of THC with 2-8% and 10-16% CBD. This strain is well-suited for those who would like to try THC for the first time, as well as experienced consumers looking to add CBD to their routine. Spectrum Green pre-rolls come in a 20x0.5g pack, and some associate spicy, woody, lemon, or fuel flavours with this strain. Tweed and 7ACRES new pre-roll offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. Spectrum products are available for purchase online at spectrumtherapeutics.com. For more information, please visit Tweed, 7ACRES. Terpene amounts may vary on a per Lot basis due to the natural variability of cannabis plants.
お知らせ • Aug 18+ 1 more updateCanopy Growth Corporation Announces Executive ChangesOn August 14, 2023, Thomas Stewart, who had been serving as the Canopy Growth Corporation’s Chief Accounting Officer and Principal Accounting Officer, transitioned to the position of Vice President, Finance of the Company and is no longer serving as the Company’s Principal Accounting Officer as of such date. Effective as of Mr. Stewart’s transition on August 14, 2023, Judy Hong, the Company’s Chief Financial Officer (“CFO”) and Principal Financial Officer, was designated as the Company’s Principal Accounting Officer. Judy Hong has served as the Company’s CFO since November 2021. Having joined the Company in December 2019 to lead Canopy’s Investor Relations team prior to being named CFO, Ms. Hong’s deep knowledge of the consumer packaged goods sector has been integral in shaping the Company’s overall commercial strategy and guiding the Company’s engagement with the financial community. Ms. Hong’s financial and capital markets experience was built during her over 20 years’ experience at Goldman Sachs & Co. Ms. Hong’s roles at Goldman Sachs & Co. included serving as a Managing Director, in the Global Investment Research Division, from 2013 until her departure in 2019. During this time, Ms. Hong covered the Beverage and Tobacco sectors in the Consumer Products and Retail team within Global Investment Research and has been ranked in The Wall Street Journal’s “Best on the Street.” Ms. Hong earned an MBA from New York University’s Stern School of Business and a BS in Communications from Cornell University. From September 2014 to January 2020, Ms. Hong served as a Treasurer on the Board of Directors of Bottomless Closet, a non-profit organization based in New York.
